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The prostacyclin (IP) receptor is a G protein coupled receptor (GPCR) which belongs 
to the family of prostanoid receptors. The IP-receptor preferentially stimulates 
adenylyl cyclase through coupling to Gs but can also directly stimulate 
phospholipase C through coupling to Gq. GPCRs can activate a series of kinases 
known as mitogen-activated protein kinases (MAPKs) which act in a cell-specific 
manner due to preferential activation of different Raf isoforms. 
The aim of my study is to examine the ability of IP-receptors to regulate the 
extracellular signal-regulated kinase (ERK) 1/2 cascade and attempt to define any 
crosstalk between Gs- and Gq-mediated signaling pathways in transient transfection 
systems and in neuronal cells endogenously expressing IP-receptors. 
Chinese hamster ovary (CHO) cells were transiently transfected with mouse 
IP-receptor cDNA (mlP-CHO cells), and reagents of PathDetect TVaw^s-Reporting 
system (Stratagene) for determination of ERKl/2 activation. The IP-receptor agonist 
cicaprost was found to stimulate ERKl/2 in mlP-CHO cells in a concentration-
dependent manner. To determine if this activation of ERKl/2 proceeded via IP-
receptor coupling to Gs, I studied the effect of protein kinase A (PKA) activators and 
inhibitors. To study the Gq-mediated pathway, a PKC activator and two protein 
kinase C (PKC) inhibitors were tested. In contrast to the inhibitory effect of PKC 
inhibitors, the two PKA inhibitors tested had no effect on cicaprost-stimulated 
ERKl/2 activity. The PKC activator produced a huge increase in ERKl/2 activity, 
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while activation of adenylyl cyclase had no effect alone, but inhibited cicaprost-
stimulated ERKl/2. 
In addition, Western blotting techniques were used to investigate EP-receptor 
regulation of ERKl/2 activity in human IP-receptor cDNA transfected CHO cells 
(hIP-CHO) and two neuronal cell lines which endogenously express IP-receptors. 
Cicaprost produced a time-dependent increase in ERKl/2 activation in hIP-CHO 
cells. Human neuroblastoma (SK-N-SH) cells did not show cicaprost-stimulated 
ERKl/2 activity, presumably due to the failure of IP-receptors to couple to Gq in 
these cells. Since IP-receptors couple robustly to Gq in rat/mouse 
neuroblastoma/glioma hybrid (NG108-15) cells, the observed lack of response to 
cicaprost and the PKC activator was unexpected. The failure to activate ERKl/2 
through PKC in NG108-15 cells is being investigated. 
In conclusion, mouse IP-receptors expressed in CHO cells appear to stimulate 
ERKl/2 through coupling to Gq proteins, and this response is likely to be attenuated 
by the simultaneous activation of Gs. Human IP-receptors expressed in CHO cells 
also appear to stimulate ERKl/2 and the mechanism involved is still being 
investigated. However, there is presently no evidence for IP-receptor stimulation of 























此 ’ NG108-15細胞內之ERK1/2的調節機制還需作進一步硏究。 
總之’鼠 IP受體於CHO細胞內能透過與Gq蛋白聯結從而激活 
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AC Adenylyl cyclase 
ATP Adenosine triphosphate 
[Ca2+]i Intracellular free calcium ion concentration 
CHO Chinese hamster ovary cells 
CLB Cell Lysis Buffer 
COX Cyclo-oxygenase 
CNS Central nervous system 
Cyclic AMP Cyclic-3,5-adenosine monophosphate 
DAG Diacylglycerol 
DMEM Dulbecco's modified Eagles medium 
DMSO Dimethyl sulphoxide 
DRG Dorsal root ganglion 
EC50 The concentration of agonist producing 50% maximal response 
EGF Epidermal growth factor 
ERK Extracellular signal-regulated kinase 
GEF GDP/GTP exchange factor 
GPCR G protein-coupled receptor 
Grb Growth factor receptor binding protein 
hlP-receptor Human prostacyclin receptor 
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PTCA Percutaneous transluminal coronary angioplasty 
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RTK Receptor tyrosine kinase 
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Chapter 1 
Introduction 
1.1 G PROTEIN-COUPLED RECEPTORS 
1.1.1 Introduction 
G protein-coupled receptors (GPCRs) constitute the largest family of cell-surface 
molecules involved in transduction of signals from the extracellular environment 
across the plasma membrane barrier and into intracellular signaling networks. A 
wide variety of external stimuli, including neurotransmitters and hormones, can act 
through GPCRs to giving rise to remarkably diverse physiological functions. About 
1% (1000) of all genes present in a mammalian genome code for GPCRs (Wess, 
1998). 
All GPCRs share a common three-dimensional structure consisting of seven 
transmembrane a-helices linked by alternating three intracellular and three 
extracellular loops including a cytoplasmic carboxyl terminus and an extracellular 
amino terminus. The extracellular receptor surface (including the extracellular N-
terminal domain and different extracellular loops) are known to be critically involved 
in ligand binding (Coughlin, 1994; Schwartz, 1994; Strader et ai, 1994; Wess, 1996). 
Moreover, the intracellular receptor surface (including the intracellular C-terminal 
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domain, second and third intracellular loops and the cytoplasmic ends of various 
transmembrane domains) is known to be important for G protein recognition and 
activation (Conklin et ai, 1993; Dohlman et al, 1991; Hedin et ai, 1993; Savarese 
et aL, 1992; Wess，1997). 
Different classification schemes can be used to subdivide the GPCR families, 
such as ligand structure, degree of amino acid similarity, and G protein coupling 
properties. For example, based on the sequence similarity, GPCRs can be divided 
into four groups. The rhodopsin-type receptors (Class I), such as prostanoid receptors, 
belong to the largest receptor family and ligands acting on these receptors show a 
remarkable structural diversity. Class I receptors have a highly conserved set of 
about 20 amino acids with several proline residues which are located in the 
cytoplasmic half of the transmembrane receptor core (Wess, 1998). Class II is the 
secretin/glucagon receptor family making up a relatively small group of peptide 
receptors. These receptors also have about 20 identical amino acids and a relatively 
large N-terminal extracellular domain containing 6 well-conserved cysteine residues 
(Laburthe et al., 1996). Class III receptors have an extraordinarily long N-terminal 
extracellular domain that has been implicated in ligand binding (Wess, 1998). Class 
IV receptors are formed by a group of about 30-40 putative pheromone receptors that 
are selectively expressed in apical neurons of the vomeronasal organ (Dulac et al., 
1995). Receptors of this class have a relatively short N-terminal extracellular 
segment and share between 47-87% sequence identity (Wess, 1998). 
GPCRs can also be classified by their G protein coupling properties. When 
activated by appropriate ligands, most GPCRs can activate only a limited set of G 
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proteins. On the basis of G protein coupling preference, GPCRs can be broadly 
divided into Gs-, Gi/o- and Gq/11-coupled receptor families. Although it has been 
reported that several different GPCRs can activate G12/13 proteins, receptors that 
preferentially activate the G12/13 family have not yet been identified (Hur et al, 
2002). Detailed information about different G proteins will be discussed in the next 
section. 
1.1.2 Heterotrimeric G proteins 
G proteins are members of a superfamily of GTPases, which interact with guanine 
nucleotides, GTP and GDP. Heterotrimeric G proteins are associated with the plasma 
membrane, and are composed of monomer a- , (3- and y-subunits; the p- and y-
subunits are tightly associated as a dimer. A receptor activated by its appropriate 
ligand interacts catalytically with specific G proteins to mediate guanine nucleotide 
exchange at the GDP/GTP binding site of the G protein a-subunit, thus displacing 
the bound GDP for GTP. The N-terminal domain of the a-subunit is the region 
where the p- and y-subunits bind. The N-terminal itself is post-translationally 
modified by myristoylation or other fatty acylation. The function of this group is to 
anchor the a-subunit, which is hydrophilic, to the cell membrane; a-subunits are also 
confined to the inner surface of the cell membrane by association with py-subunits. 
Except in the retinal rhodopsin-transducin-phosphodiesterase system, the a-subunit 
remains associated with the membrane, even when activated and dissociated from 
py-subunits (Dolphin, 1996). The GTP bound form of the a-subunits dissociates 
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from the receptor as well as the Py-subunits and alters the activity of specific effector 
molecules; typically adenylyl cyclase and phospholipase C. 
The subunits of the heterotrimeric G proteins show a wide range of 
heterogeneity. At least 20 different a-subunits (encoded by 17 distinct genes), six (3-
subunits and 12 y-subunits have been identified (Clapham et al,, 1997; Radhika et ai, 
2001). The heterogeneity of the a-subunits has been used to denote and classify the 
G proteins. The amino acids of a-subunits share 50% or more identity and are 
grouped into four major families: Gs, Gi/o, Gq/11 and G12/13 (Neer, 1995). The Gs 
family includes several splice variants of as and aolf while the Gi/o family consists 
of three distinct ai species (a i l , ai2 and ai3) and two ao variants (aol and ao2). 
The individual members of the Gq/11 family are aq, a l l , al4，al5 and a l 6 while 
the G12/13 family consist of a l 2 and a l 3 (Wess, 1998). The different P-subunits 
shares a relatively high degree of sequence identity, while various y-subunits are 
structurally more diverse. Theoretically, the diversity of the (3- and y-subunits allow 
for the formation of 72 different Py dimer complexes. The potential functional 
importance of such diversity is unclear at present, as most py complexes appear to 
exhibit similar functional properties. The Py complexes are extremely stable and 
usually are regarded as one functional unit. 
1.1.3 Second messenger systems 
GPCRs interact with heterotrimeric G proteins to stimulate different effector 
molecules which include adenylyl cyclases, phospholipase A2, phospholipase C and 
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phosphoinositide 3-kinase, thereby activating or inhibiting the production of a variety 
of second messengers such as cyclic AMP，diacylglycerol, inositol (1,4,5)-
trisphosphate, inositol (3,4,5)-trisphosphate, arachidonic acid and phosphatidic acid, 
in addition to promoting increases in the intracellular concentration of calcium and 
the opening or closing of a variety of ion channels. Two of these effector systems 
will be briefly introduced in this section. 
The adenylyl cyclase system 
The 120-kilo dalton-adenylyl cyclase (AC) is a single polypeptide enzyme, which 
catalyzes the formation of cyclic AMP from ATP. At least nine closely related 
isoforms of mammalian AC, (AC1-AC9), and two splice variants of ACS, have been 
cloned and characterized in mammals (Hanoune et al., 1997; Iyengar, 1993; Simonds, 
1999; Sunahara et al” 1996). All of these AC isoforms share a large sequence 
homology in the primary structure of their catalytic site and the same predicted three-
dimensional structure (Defer et al., 2000). The primary structure of AC consists of 
two transmembrane regions, Mi and M2, and two cytoplasmic regions, Ci and C2 
(Krupinski et al, 1989). Cyclic AMP is produced continuously and inactivated by 
hydrolysis to 5'-AMP, by the action of a family of enzymes known as 
phosphodiesterases. Cyclic AMP in turn activates a cytoplasmic cyclic AMP-
dependent protein kinase (PKA) by attaching to two regulatory subunits of the kinase 
and releasing two catalytic subunits that promote phosphorylation of serine residues 
on proteins (Krebs, 1989). This phosphorylation step controls a variety of activities, 
depending on the particular tissue involved. 
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The phospholipase C system 
In the late 1980s and early 1990s, three mammalian phospholipase C (PLC) subtypes, 
P, Y and 6 were isolated and their corresponding cDNA sequences determined (Rhee 
et ai, 1992). The PLC enzymes share some common structural features including 
two regions of conserved sequence, termed "X" and “Y” domains, that contain 
residues important for substrate binding and catalysis (Moms et ai, 1999). Under the 
control of cell surface receptors, these enzymes hydrolyse the highly phosphorylated 
lipid phosphatidylinositol 4,5-bisphosphate (PIP2), generating two intracellular 
products: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 is 
important in stimulation of intracellular calcium release from the endoplasmic 
reticulum (Morris et al., 1999). The calcium release thus enhances the activity of 
protein kinase C (PKC). As an activator of PKC, DAG greatly increases the affinity 
of PKC for calcium ions (Lee et al., 1994b). PKC phosphorylates specific serine and 
threonine residues in target proteins such as calmodulin, and further transmits the 
signal to intracellular level. 
1.1.4 Mechanism of GPCR activation 
Agonist-activation of GPCRs is considered as a ternary complex model, which 
accounts for the cooperative interactions among agonist, receptor and G protein (De 
Lean et al., 1980). The better this ternary complex is stabilized, the more efficacious 
is the agonist. The formation of this activated state of the receptor must involve a 
series of interactions between the agonist and amino acid side chains of the receptor 
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(Strange, 1996). The activation process can be divided into different stages. Agonist 
first interacts with the free receptor to form an agonist/receptor complex. Interaction 
with the agonist/receptor complex and G protein leads to formation of the activated 
ternary complex. 
In the 'resting' state (Fig. 1.1)，the G protein exists as an unattached aPy 
trimer with GDP bound on the a-subunit. When a receptor is activated by an agonist 
molecule, a cytoplasmic conformational change of receptor occurs (Fig. 1.1). This 
change causes the receptor to acquire high affinity for apy. Association of aPy with 
the receptor causes the bound GDP to dissociate and to be replaced with GTP, which 
in turn causes dissociation of the G protein trimer. The active form of G protein (that 
is the released GTP-a and f>y subunits) diffuse in the membrane and can associate 
with various enzymes and ion channels (Target 1 and 2) causing activation or 
inactivation depending on the specific effector system. 
The process is terminated when the hydrolysis of GTP to GDP occurs 
through the GTPase activity of the a-subunit. The resulting GDP-a then dissociates 
from the effector, and reunites with a Py-subunit, completing the cycle. Attachment 
of the a-subunit to an effector molecule actually increases its GTPase activity, the 
magnitude of this increase being different for different types of effector. Since GTP 
hydrolysis is the step that terminates the ability of the a-subunit to produce it effect, 
regulation of its GTPase activity by the effector protein means that activation of the 
effector tends to be self-limiting (Rang et al.，1999). 
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Figure 1.1 Mechanism of GPCR activation. The activated state of target proteins is 
shown in black. Figure adapted from Rang et al. (1999). 
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1.2 PROSTACYCLIN AND ITS RECEPTORS 
Prostanoid receptors were initially characterized pharmacologically in several 
bioassay systems, including contraction-relaxation assays on various smooth muscles 
and the aggregation of platelets. These receptors are classified into five basic types, 
termed DP, EP, FP, IP and TP, on the basis of their sensitivity to the five primary 
prostanoids, PGD2, PGE2, ？GYja, PGI2 and TXA2, respectively under lUPHAR 
classification. The EP receptor is subdivided into four subtypes, EP!，EP2, EP3 and 
EP4, on the basis of their responses to various agonists and antagonists (Coleman et 
al., 1994). Although the overall homology of amino acid sequences among the 
prostanoid receptors ranges from approximately 20% to 30%, the prostanoid 
receptors show significantly higher homology to each other than other rhodopsin-
type receptors (Narumiya et al, 1999). 
1.2.1 General properties of prostacyclin 
1.2.1.1 Synthesis of prostacyclin 
When tissues are exposed to diverse physiological and pathological stimuli, the 20-
carbon unsaturated fatty acid, arachidonic acid, is liberated from membrane 
phospholipids by the action of phospholipase A2, Arachidonic acid is then 
metabolized by cyclo-oxygenase (COX) to produce an unstable endoperoxide 
intermediate PGH2 which in turn is converted to various prostanoids by their 
respective synthases, producing prostaglandins (PGD2, PGE2, PGFia, PGI2) and 
thromboxane A2 (TXA2) (Narumiya et al., 1999). The chemically unstable 
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prostacyclin (PGI2) (Fig. 1.2) is catalysed by prostacyclin synthase from PGH2, and 
is hydrolysed under physiological conditions with a biological half-life of 2-3 
minutes, breaking down to form 6-oxo-PGFia (Moncada, 1982). The prostacyclin 
synthase gene is located on human chromosome 20 (Wang et aL, 1996). The 
prostacyclin synthase mRNA is widely expressed in human tissue especially in heart, 
skeletal muscle and lung, which have a high blood flow per mass of tissue (Tanabe et 
al； 1995). 
Prostacyclin plays a major physiological role as a potent mediator of 
vasodilation and an inhibitor of platelet activation (Moncada, 1982). In blood vessels, 
prostacyclin is produced by endothelial cells and inhibits platelet aggregation and 
induces vasodilation by activating adenylyl cyclase and generating cyclic AMP. 
These actions can counteract the proaggregatory and vasoconstrictor activities of 
another unstable prostanoid, TXA2, and contributes to the maintenance of 
homeostasis in circulation (Moncada, 1982). These activities of prostacyclin have 
been regarded as potentially useful in preventing and managing diseases such as 
cerebral thrombosis and myocardial infarction, and many stable analogoues of 
prostacyclin have been synthesized as potential drugs (Wise & Jones, 2000). 
1.2.1.2 Prostacyclin analogues 
The action of prostacyclin is mediated through specific cell surface prostacyclin (IP) 
receptors. Prostacyclin is chemically unstable with a short half-life and able to 
stimulate other prostanoid receptors (Dong et al., 1986)，therefore it is difficult to use 
experimentally. A number of stable prostacyclin analogues have been developed 
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such as carbacyclin (Whittle et ai, 1985; Whittle et ai, 1980), cicaprost 
(Sturzebecher et ai, 1986) and iloprost (Schror et ai, 1981). The IP-receptor is 
selectively activated by cicaprost (Fig. 1.2) (Kiriyama et al., 1997). Iloprost and 
carbacyclin activate the IP-receptor but activate the EPi-receptor as well (Kiriyama 
et al, 1997). Among these prostacyclin analogues, cicaprost is more commonly used 
in IP-receptor characterization studies simply because of its high potency and 
selectivity compared to other analogues. The binding affinities of prostacyclin 
analogues for different human and mouse IP- and EP-receptor subtypes are shown in 
Table 1.1. 
In ligand binding studies using cloned human prostanoid receptors, cicaprost 
and iloprost showed high affinity for hIP-receptor in HEK293 cells (Abramovitz et 
al., 2000)，and mlP-receptors in CHO cells (Kiriyama et al., 1997). Similar studies 
showed cicaprost has least affinity to the EP-receptor subtypes compared with other 
prostacyclin analogues and thus it is an advantage using cicaprost to study the 
activity of IP-receptors. For example, cicaprost lacks affinity for the human and 
mouse EPi-receptors (Abramovitz et al., 2000; Breyer et al., 2001). Also cicaprost 
has less affinity for the human and mouse EPs-receptor than other prostacyclin 
analogues. Summarizing all the results, cicaprost is much more preferred for the 
study of human or mouse IP-receptors. 
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1.2.2 Characterization of IP-receptors 
1.2.2.1 Distribution of IP-receptors 
In order to understand the functional importance of IP-receptors, the distribution of 
IP-receptors has been studied by Northern blot and in situ hybridization analysis of 
their mRNA expression. Although the mRNA expression of IP-receptor usually 
depends on the sensitivity of assay system, detection of IP-receptor mRNA in an 
unexpected location can provide important information about the contribution of IP-
receptors in those cells or tissues. The mRNA expression level of the IP-receptor 
also varies in different species. For example, the mouse IP-receptor mRNA 
expression is most abundant in the thymus and spleen (Hirata et al., 1995)，but it is 
undetectable in the human thymus. For rat IP-receptors, they can be detected in 
thymus, but are far more abundant in rat aorta and lung (Nakagawa et al” 1995). 
Difference in IP-receptor mRNA expression levels might just reflect different stages 
of maturation of thymocytes in lymphatic organs of different species (Hirata et aL, 
1995). However, the function of IP-receptors in lymphocytes remains unknown. 
Moreover, in human liver and kidney, high mRNA expression levels of IP-receptors 
are found, but there is a lack of expression of IP-receptor mRNA in mouse and rat 
liver and kidney (Hirata et aL, 1995). The different expression level of EP-receptor 
mRNA in human and mouse kidney may reflect the relative abundance of 
prostacyclin synthase expression in human glomeruli or glomerular cells (Komhoff 
et aL, 1998). 
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The mRNA expression of human IP-receptor has been detected in a wide 
range of megakaryocytic (e.g. MEG-01) and megakaryocytic/erythroid (e.g. HEL) 
cell lines and human cord blood megakaryocytes, indicating the significance of IP-
receptor within vascular systems (Schwaner et al., 1992). In addition, human EP-
receptor mRNA expression can be up-regulated by cytokines in 
megakaryocytopoiesis (Sasaki et al., 1997), thus proposing the role of IP-receptor in 
regulating homeostasis. 
IP-receptor mRNA is also abundantly expressed in neuronal dorsal root 
ganglion (DRG) cells (Oida et al., 1995). About 40% of neurones in mouse DRG 
expressed IP-receptor mRNA. About 30% of the neurones contained the mRNA for 
the Substance P precursor, preprotachykinin A (PPTA), and about 70% of the 
substance P-containing cells co-expressed IP-receptor mRNA. This evidence 
therefore suggests a role of these IP-receptors in the transmission of sensory signals 
in the mediation of pain (Oida et al., 1995). 
IP-receptor was also reported in the rat central nervous system by in vitro 
autoradiography using [^H]-iloprost. High density binding was found in the nucleus 
of the solitary tract (NTS) and in the spinal trigeminal nucleus in the lower brain 
stem as well as in the dorsal horn of the spinal cord. A much weaker binding was 
found in thalamus and cerebral cortex (Matsumura et al., 1995). With the use of the 
[^H]-isocarbacyclin, a prostacyclin analogue, it was suggested that at least two 
distinct IP-receptors exist in the brain, which activate different signal transduction 
pathways (Takechi et al., 1996). Using [^H]-isocarbacyclin, its binding affinity was 
much higher than that of [^H]-iloprost in the thalamus and cerebal cortex, where both 
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ligands showed comparable binding in some regions of the medulla and spinal cord 
(Takechi et al, 1996). Takechi suggests that several brain area except in the nucleus 
of the solitary tract and spinal trigeminal nucleus express IP-receptor subtype, which 
activate different signal transduction pathway compared with platelet-like IP-
receptor (Takechi et al., 1996). Without the cloned IP-receptor subtype, further 
molecular and pharmacological study should be used to clarify the existence of EP-
receptor subtypes. � 
1.2.2.2 Cloning of IP-receptors 
The IP-receptor belongs to the family of GPCRs and was one of the last of the 
prostanoid receptor family to be cloned. It was first cloned from mice in 1994 
(Namba et al., 1994) followed by the isolation of human (Boie et al., 1994; 
Katsuyama et al., 1994; Nakagawa et al, 1994), rat (Sasaki et aL, 1994) and bovine 
(Hasse et al., 1997) cDNA for CP-receptors. The amino acid sequences in the 
transmembrane domains are relatively conserved among various prostanoid receptor 
types and subtypes (Watabe et aL, 1993) especially the highly conserved amino acid 
sequences in the second and the seventh transmembrane domain of EP- and TP-
receptors receptors (Negishi et al., 1995; Ushikubi et aL, 1995). Using these 
conserved sequences as oligonucleotides primers, the mouse IP-receptor cDNA was 
first amplified by reverse transcription polymerase chain reaction (RT-PCR) from 
total RNA of cultured P-815 mouse mastocytoma cells which express high levels of 
IP-receptors (Hashimoto et al., 1990). The cloned cDNA nucleotides were then 
confirmed by hybridization screening in a P-815 cDNA library and restriction 
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enzyme mapping followed by sequence analysis (Namba et al., 1994). Human IP-
receptor cDNA has also been isolated from cDNA libraries prepared from a 
megakaryoblastic leukaemia cell line and human lung (Boie et al, 1994; Katsuyama 
et al., 1994; Nakagawa et al, 1994). Cross-hybridization of rat cDNA libraries with 
a probe obtained from mouse IP-receptors cDNA sequence was used in rat IP-
receptor cloning using similar methods (Sasaki et al., 1994). 
1.2.2.3 Structure of IP-receptors 
In general, the four cloned IP-receptors are very similar to each other in their primary 
structure. They have the putative N-glycosylation sites within the N-terminus of the 
extracellular portion of IP-receptor. Putative phosphorylation sites are widely 
distributed in the cytoplasmic portion of the IP-receptor (Namba et al., 1994). In 
addition, with the use of IP/DP chimeric receptor, the ligand binding pocket of IP-
receptor is formed mainly by the second, sixth and seventh transmembrane domains, 
of which the former is involved in the recognition of the ring structure and the latter 
two in that one of the two sidechains of prostacyclin (Kobayashi et al., 1997; 
Kobayashi et al., 2000). 
A typical IP-receptor structure is shown in Figure 1.3. Based on the primary 
sequence of the cloned IP-receptor, the sequence identity between the mouse and 
human IP-receptor is only 79% and most of this difference lies in the C-terminal tail 
(Wise & Jones, 2000). The human EP-receptor cDNA consists of 386 amino acid 
residues with a deduced molecular mass around 41 kDa (Boie et al., 1994)，while 
mouse and rat IP-receptor cDNA are around 44 kDa, and have 30 amino acids more 
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than human IP-receptors in the translation initiation site of N-terminus (Boie et ai, 
1994; Namba et al., 1994; Sasaki et al., 1994). Further studies showed that N-linked 
glycosylation of hIP-receptor in the N-terminus are important for membrane 
localization, ligand binding, and signal transduction (Zhang et ai, 2001). 
Chromosomal localization of the genes encoding the mouse and human prostanoid 
receptors have been determined, with the genes encoding the mouse and human IP-
receptor being mapped to chromosomes 7 (Ishikawa et al., 1996) and 19 (Duncan et 
al., 1995)，respectively. Deduced amino acid sequence showed that a potential 
phosphorylation site by PKA is found in the first cytoplasmic loop while a 
potentialial PKC phosphorylation site was found in the third cytoplasmic loop and 
t 
the C-terminal tail (Namba et al., 1994). Recent studies suggested that Ser357 
located at the C-terminal tail is critical for both PKA and PKC phosphorylation 
(Lawler et a/., 2001). 
1.2.3 Coupling of IP-receptors to G proteins 
1.2.3.1 Interaction with Gs 
i 
The findings in various systems suggest that prostacyclin stimulates adenylyl cyclase 
and increases the intracellular level of cyclic AMP (Halushka et al., 1989). This 
pathway is thought relevant to inhibition of platelet aggregation and vascular smooth 
muscle relaxation (Coleman et ai, 1990). Using CHO cells transfected with mlP-
receptor cDNA, iloprost-stimulated cyclic AMP production in a concentration 
dependent manner, while no response was found in untransfected CHO cells (Namba 
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et al., 1994). Cholera toxin, which is used to degrade Gs to prevent AC activation 
(Chang et al., 1989)，eliminated the iloprost-induced cyclic AMP generation giving 
further evidence for IP-receptors coupling to Gs proteins. 
1.2.3.2 Interaction with Gq 
The IP-receptor classically stimulates adenylyl cyclase. However, cloned hEP and 
mlP expression studies reported that IP-receptors mediated not only a rise in cyclic 
AMP levels but also activated the PLC (Namba et al., 1994; Smyth et al., 1998). IP-
receptor-induced phosphatidylinositol (PI) metabolism in CHO cells was not 
inhibited by either pertussis toxin (PTX) or cholera toxin, suggesting that the Gq 
family of G proteins is likely to be participating in this response (Namba et al., 1994). 
The biological relevance of this pathway is still unclear. The iloprost-mediated PI 
metabolism was not mimicked by the addition of dibutyryl cAMP and was not 
affected by the loss of Goes suggesting that the same IP-receptor can couple to both 
Gs and Gq (Namba et al, 1994). 
In addition to the Gq coupling with IP-receptors in transfection systems, IP-
receptors can also couple to AC- and PLC-mediated pathways in normal cells such as 
primary cultures of adult rat dorsal root ganglion (DRG) cells (Smith et al, 1998) 
and the cultured microvascular smooth muscle cells obtained from the cortex of 
piglet brain (Parfenova et al, 1996; Parkinson et al, 2000). 
Recent studies also suggest that cicaprost stimulation of mlP-HEK 293 cells 
leads to an increase in IP3 generation and mobilization of (Lawler et al.’ 
2001). PKA inhibitor (H89), but not PTX or PKC inhibitor (GF109203X), almost 
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completely abolished cicaprost mediated signaling indicating that mlP-mediated IP3 
generation and [Cd^^'l mobilization occurred in a PTX insensitive, PKC-independent, 
PKA-dependent mechanism (Lawler et aL, 2001). Similar studies showed that 
transient overexpression of Gaq in CHO cells and HEK cells increases cicaprost-
mediated IP3 generation and mobilization of (Hayes et aL, 1999; Kam et aL, 
2001). The PI-PLC inhibitor U73122 abolished cicaprost-induced 
mobilization confirming that the primary sources of mlP-mediated 
mobilization is from HVregulated intracellular stores (Lawler et al., 2001). In 
summary, mlP-receptors can couple to PLC and that PLC coupling occurs in a Gaq-
mediated, PTX insensitive, PKC-independent, but PKA-dependent manner. Studies 
with a site-directed mutant of mlP on Ser^^^ suggested that mlP-receptors interact 
with Gq following phosphorylation on Ser^^^ by PKA (Lawler et al., 2001). 
1.2.3.3 Interaction with Gi 
Hebert reported that IP-receptors couple to Gi proteins in rat medullary thick 
ascendending limb (MTAL) (Hebert et al., 1998). Iloprost and carbacyclin inhibited 
the arginine vasopressin-dependent increase in cyclic AMP production in MTAL in a 
PTX-sensitive manner, and did not activate PKC (Hebert et al., 1998). In order to 
explain the inhibitory effect of the prostacyclin analogues, three subtypes of IP-
receptor were proposed. IP 1-receptor mediated PLC activation and increase 
IP2-receptors couple to AC leading to increase in cyclic AMP and IPs-receptors 
couple to inhibition of cyclic AMP formation through a PTX-sensitive pathway. 
However, it is difficult to conclude that the coupling between CP-receptor and Gi 
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proteins occurs without the use of IP-receptor antagonists to help identify the site of 
action of the prostacyclin analogues. Moreover, it is possible that the prostacyclin 
analogues used in this study can stimulate EPs-receptors (Table 1.1), which normally 
couple to Gi to inhibit cyclic AMP formation. Also using fusion proteins between the 
IP-receptor and Gi protein, it is reported that there was no stimulation of GTPase 
activity of IP-receptor-GiiOc fusion in response to iloprost (Fong et al., 1999). Using 
CHO cells transfected with mEP-receptor cDNA, pre-treatment of PTX fail to 
influence IP agonists (cicaprost and octimibate) efficacy or potency indicating a lack 
of involvement of Gi protein (Kam et al., 2001). 
However, studies of mlP-receptors endogenously expressed in HEL cells and 
transfected in HEK 293 cells suggested that mlP-receptor inhibit adenylyl cyclase in 
a PTX-sensitive, Gai-dependent and concentration-dependent manner (Lawler et al.’ 
2001). HEK 293 cells transfected with mlP-receptor were stimulated with a range of 
cicaprost concentrations in the absence and presence of forskolin. In the absence of 
forskolin, mlP generated concentration-dependent increase in cyclic AMP production 
with coupling to Gs. However, in the presence of forskolin, stimulation of mlP at 
higher cicaprost concentration, a concentration-dependent reduction in cyclic AMP 
production indicative of mlP coupling to God was shown. PKA inhibitor (H89) or 
PTX but not PKC inhibitor (GF109203X), blocked mlP-mediated Gai coupling but 
had no effect on mlP coupling to Gas over the range of cicaprost concentrations used 
(Lawler et aL, 2001). A site-directed mutant of mlP on Ser】，？ suggested that mEP-
receptor interacted with Gi following phosphorylation on Ser^ "^^  by PKA (Lawler et 
a/., 2001). 
“ ‘ Page 19 
Chapter 1 Introduction 
1.2.3.4 Interaction with PPARs 
Prostaglandins, including prostacyclin, function through cell surface GPCRs linked 
to different signal transduction pathways (Narumiya et al., 1999) and also exert their 
effect by interacting with peroxisome proliferator-activated receptors (PPARs), 
which belongs to the nuclear hormone receptor superfamily (Mangelsdorf et cd., 
1995). Many of the functions of PPARs are associated with lipid metabolism and 
homeostasis (Issemann et al, 1990; Schoonjans et aL, 1996) while more recent 
evidence suggested that PPARs also mediate other biological function such as cell 
cycle control and the modulation of cytokine production in immune responses (Jiang 
et aL, 1998; Mueller et aL, 1998; Ricote et al, 1998; Staels et al., 1998; Tontonoz et 
al., 1998). Current studies observed that C0X2-derived prostacyclin activates the 
nuclear receptor PPAR6 for implantation and decidualization (Lim et al., 1999). 
PPAR6 is shown as a receptor for both arachidonic acid and prostacyclin. cPLA2 can 
then be translocated to the nuclear envelope and cause generation of AA in the 
nucleus, where it can bind to PPAR6. RXR-PPAR5 dimmer formation and cofactor 
recruitment induced by AA binding then stimulate the C0X2 gene expression, in 
turn enhancing AA utilization and prostacyclin generation. As prostacyclin 
accumulates, it acts as a stronger ligand for PPARS to induce target gene in 
implantation. 
1.2.4 Role of prostacyclin in mitogenesis/anti-mitogenesis 
Proliferation of vascular smooth muscle cells (SMCs) as a response to vessel injury 
is essential for stabilizing the vessel wall during the course of wound healing, 
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including endothelial injury after percutaneous transluminal coronary angioplasty 
(PTCA) (Weissberg et al., 1996). However, uncontrolled SMC proliferation may 
result in critical vessel narrowing, eventually resulting in restenosis (Bauters et al,, 
1996). Growth of SMCs in response to injury is regulated by humoral and cellular 
factors. Specifically, vascular cells themselves are able to regulate cytoskeletal 
structures and differentiation state by generating positive and negative differentiation 
signals. There is evidence suggesting that vasoconstrictor compounds such as TXA2 
act as growth promoting agents while vasodilator compounds such as prostacyclin 
have the opposite effect (Wu, 1995). 
The control of SMC proliferation by prostacyclin and its analogues such as 
carbacyclin have been shown to inhibit proliferation of vascular SMCs after 
stimulation with growth factors (Nakaki et al” 1991; Southgate et al, 1990). There 
are few reports showing a stimulation of SMC proliferation rather than inhibition by 
prostacyclin (Palmberg et al., 1991). With a few exceptions, prostacyclin acts as 
antiproliferative signal and antagonises the mitogenic action of growth factors on 
vascular SMCs (Schror et al., 1997). From the cell culture studies which have been 
done, species variations, different experimental protocols, specifically the presence 
or absence of growth factors to stimulate DNA synthesis, will markedly influence 
growth responses (Campbell et al., 1993). 
Antiproliferation actions of prostacyclin were also observed in vivo. Oral 
treatment of cholestesterol-fed rabbits with cicaprost at a non-hypotensive dose for 3 
months was found to significantly reduce aortic plaque formation and intima 
thickening as well as to improve endothelium-dependent vasodilation in both aortic 
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tissue and coronary arteries (Braun et al., 1993). Thus, treatment with cicaprost did 
not only modify smooth muscle cell proliferation but also had beneficial effects on 
the endothelium (Schror et al., 1997). 
Many of vascular cell and blood cell actions of prostacyclin are due to Gs-
coupled adenylyl cyclase stimulation (Schror et al., 1997). Cyclic AMP was 
considered to have growth modulating effect (Assender et ai, 1992). It has been 
reported that adenylyl cyclase activity and DNA synthesis are stimulated in parallel 
by growth factors in vascular SMCs (Franks et al.，1984). 
Another signalling pathway related to mitogenic stimuli is the Gq-mediated 
PLC pathway. It has been shown that activation of PKC by phorbol ester enhanced 
prostacyclin analogue (OP-41483)-induced cyclic AMP accumulation in vascular 
SMCs and at the same time enhanced its antimitogenic effect (Fukuo et al, 1994). 
However, PKC has been shown to exert both proliferation and antiproliferation 
effects on cultured vascular SMCs (Lee et al., 1994b) and the involvement of Ca^^-
activated PKC in control of proliferation also depends on the type of mitogen. Thus, 
there is no definite conclusion on the involvement of PKC in prostacyclin-induced 
modulation of mitogenesis (Schror et al., 1997). 
Growth factors, such as platelet-derived growth factor (PDGF), generally act 
via tyrosine kinase receptor that are coupled to the extracellular-regulated protein 
kinase (ERK) cascade as the major signal transduction pathway (Davis, 1993). PDGF 
is also generated by vascular SMCs themselves after injury (Walker et al., 1986). 
Stimulation of ERK by growth factors follows activation of the Ras/Raf pathway 
(see section 1.3.1.1). It has been shown that phosphorylation of Raf-1 by PKA results 
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in subsequent inhibition of ERK pathway signalling to the cell nucleus (Graves et al, 
1993; Sevetson et al., 1993; Wu et ai, 1993b). This raises the possibility that 
vasodilatory prostacyclin might inhibit Ras by cyclic AMP-dependent 
phosphorylation of Raf-1 (Schror et aL, 1997). Detailed information of the ERK 
cascade will be discussed in the next section. 
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Figure 1.2 Chemical structure of prostacyclin and cicaprost 
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Figure 1.3 Amino acid sequence of mouse prostacyclin receptor (mlP). (A) and (B) 
are the proposed phosphorylation site for PKA and PKC, respectively (Namba et al., 
1994) while (C) was shown as a PKA phosphorylation site and essential for Gai and 
Gaq interaction (Lawler et al, 2001). 
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1.3 SIGNAL TRANSDUCTION NETWORK OF M A R K FAMILY 
Every cell in the human body has a vast array of signal transduction systems. Cells 
have developed a variety of molecules to respond to their environment and 
intracellular signaling networks that relay the extracellular information to different 
subcellular compartments and transduce this information into the nucleus, where it is 
translated into specific genomic responses. Among the different intracellular 
signaling systems known, phosphorylation cascades are commonly used, particularly 
cascades involving protein kinases of the mitogen-activated protein kinase (MAPK) 
family (Brunet et al., 1997). The MAPKs are ubiquitous proteins that transduce 
extracellular signals leading to a variety of cellular responses including proliferation 
and differentiation (Kyriakis et aL, 1994; Leppa et al., 1998; Pages et aL, 1993; 
Widegren et a/., 2001). 
The mammalian MAPK family includes extracelluar signal-regulated kinases 
(ERK) 1 and ERK2 (ERKl/2), often referred to as p44 and p42 MAPKs; three genes 
encoding 10 or more splice variants of the c-Jun N-terminal kinase or stress-activated 
protein kinases (JNK/SAPKs); four isoforms o fp38 MAPK (SAPK3) designated a , 
P, Y, 5 (Rouse et aL, 1994) and an uncharacterised protein ERK5 (BMKl) (English et 
aL, 1999b). Analysis of 5. cerevisiae and Caenorhapditis elegans genome sequences 
indicates the presence of at least five and more than a dozen MAPK genes, 
respectively, in these two species (Hunter et al.’ 1997). A prediction of 40 or more 
mammalian MAPK genes seems reasonable based on the greater complexity of 
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mammalian genomes (English et al., 1999a). A general picture summarizing the 
MAPK pathways is shown in Figure 1.3. 
The first mammalian MAPKs to be cloned were ERKl and 2 in the early 
1990s, facilitating the development of reagents for their study and revealing the 
relationship of the MAPK cascade to the mating pathway in yeast (Boulton et aL, 
1991;Boulton et aL, 1990). 
A second subgroup of MAPKs, the JNK family was discovered as a 
cycloheximide-activated proline-directed kinase and as an activity that bound to and 
phosphorylated the N-terminal sites of c-Jun following exposure of cells to 
ultraviolet (UV) light (Hibi et al,, 1993; Kyriakis et al., 1990). The cDNA cloning 
revealed three genes, which encode the 46- and 54-kDa isoforms of JNK (Derijard et 
al, 1994; Kyriakis et al, 1994). These enzymes are activated by UV, cytokines and 
other environmental stressors. JNK is important for cytokine biosynthesis and is 
involved in cell transformation and stress responses (Dong et al., 1998; Kyriakis et 
al., 1990). 
The p38 subgroup of MAPKs was discovered as a lipopolysacharide (LPS)-
induced tyrosine phosphoprotein and as the target of a drug developed to inhibited 
LPS-induced tumor necrosis factor-a biosynthesis (Han et al., 1994; Lee et al., 
1994a). Like the JNK family members, p38 isoforms are often activated by cellular 
stresses and are also referred to as stress-activated protein kinases (SAPK). In 
addition to their roles in cytokine biosynthesis, they have been implicated in skeletal 
muscle differentiation and B cell proliferation (Craxton et al, 1998; Zetser et aL, 
1999). 
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The less understood MAPK, ERJC5, has been implicated in cell cycle control 
and cell transformation (English et al, 1999b; Kato et al., 1998). At the present time, 
there is relatively little information on ERK5. Therefore, I will not discuss ERK5 
further. 
1.3.1 MAPK modules in mammalian cells 
While MAPK signals lead to diverse downstream events, the MAPK cascades share 
a common skeleton consisting of at least three protein kinase modules that work in 
series and three enzymes comprise a cascade (Widmann et ai, 1999). A defining 
characteristic of a MAPK cascade is the requirement of dual phosphorylation of a 
threonine-X-tyrosine (thr-X-tyr) motif for full enzyme activation, where X can be 
different amino acids among different MAPKs (Widegren et al., 2001). A 
serine/threonine kinase (MAPK kinase kinase, MEKK or MKKK) phosphorylates a 
dual-specificity threonine and tyrosine kinase (MAPK kinase or MKK) on two serine 
or threonine residues, resulting in its activation. This dual-specificity kinase in turn 
phosphorylates and activates a serine/threonine kinase (MAPK) on two 
phosphorylation sites within a thr-X-tyr motif adjacent to the catalytic cleft of the 
kinase (Hanks et aL, 1988). Different MAPK cascades are distinguished by the 
sequence of the tripeptide dual phosphorylation motif that is required for MAPK 
activation: Thr-Glu-Tyr (ERKl/2) (Cobb et ai, 1991), Thr-Pro-Tyr (JNK) (Derijard 
et al.’ 1994; Kyriakis et al, 1994)，and Thr-Gly-Tyr (p38) (Han et aL, 1994; Rouse et 
aL, 1994; Derijard et al., 1995). 
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MKKKs are not abundant enzymes. Both MKK and MAPK are much more 
abundant and are roughly equimolar in many cell types (Ferrell, 1996; Huang et al., 
1996). Thus, only the first step of this cascade amplifies the final components in the 
cascade. The second step in the modules builds in mechanisms for cooperative 
activation of MAPKs over a narrow range of input signal and for creating a threshold 
to filter noise from subthreshold signals (Ferrell, 1997; Ferrell et al.’ 1997; Ferrell et 
cd., 1998). 
Although the different MAPK cascades are very similar, they are activated by 
different external stimuli to give different responses. The aim of this section is to 
introduce briefly the different MAPK pathways and focus on the signaling pathway 
of ERK cascades activated by GPCRs in mammalian cells. 
1.3.1.1 Extracellular regulated kinase (ERK) cascade 
The discovery of the first mammalian MAPK module in 1987 was based on the 
identification of p42 and p44 MAPKs (Ray et aL, 1987). The two closely related 
MAPK isoforms were also called ERK2 and ERKl, respectively (Boulton et aL, 
1991). ERKl and 2 are proteins that are nearly 85% identical overall, with much 
greater identity in core regions involved in binding substrates (Boulton et al, 1991; 
Boulton et al.’ 1990). Regulation of the ERK 1/2 cascade is complex (Fig. 1.4). 
ERK 1/2 signaling is the most characterized MAPK pathway in mammalian 
cells and is activated through growth factors such as epidermal growth factor that 
activate tyrosine kinase receptors (Cobb et aL, 1995; Seger et al., 1995). Classical 
receptor tyrosine kinase activation of ERK 1/2 is initiated by receptor 
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autophosphorylation on tyrosine residues, which creates docking sites for signal 
transducers and adapters. Adapter molecules, such as growth factor receptor binding 
protein (Grb) or Src homologous and collagen (She) (Pawson et al., 1997)，bind 
through phosphotyrosine binding domains such as Src homology domain (SH) 2- and 
SH3-domains (Skolnik et al., 1993) to form a complex. This complex associates with 
the guanine nucleotide exchange factor son of sevenless (SOS) (Li et al” 1993; 
Pawson et al., 1997) at the plasma membrane to activate the small G protein Ras. 
SOS catalyzes the GDP release and GTP binding to Ras resulting in conversion of 
the inactive GDP-Ras to active GTP-Ras. The GTP-bound form of Ras binds to its 
effectors, notably Raf-1 (Jelinek et al., 1996), bringing it to the plasma membrane. 
At this location its protein kinase activity is increased by one or several mechanisms 
including phosphorylation, therefore, activating the first tier of the protein kinase 
cascade (Moodie et al., 1993; Morrison et al., 1997; Vojtek et al, 1993; Wame et al, 
1993; Zhang et al., 1993). 
The Raf family of protein kinases is composed of A-Raf, B-Raf and Raf-1 (c-
Raf) (Hagemann et al., 1999; Morrison et al., 1997). Each isoform contains three 
conserved regions (termed CRl, CR2 and CR3), the first two conserved regions are 
located in the amino terminus and have been implicated in regulating the Raf 
catalytic domain, because their deletion creates a mutant of Raf-1 that either has 
constitutively high activity or can be activated in a Ras-independent manner (Leevers 
et al., 1994; Whitehurst et al, 1995). The kinase domain is located in CR3. Raf-1 is 
ubiquitous; highest expression of B-Raf occurs in neuronal tissue and testis; and A-
Raf appears to function primarily in urogenital tissue (Pearson et al, 2001). There 
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are significant differences in the regulation of Raf isoforms. One notable difference 
between Raf-1 and B-Raf is their differential regulation by the small G proteins Ras 
and Rapl (de Rooij et al., 1998; Erhardt et al., 1995; Seidel et al., 1999; Vossler et 
al., 1997; Zwartkruis et al, 1998). Raf-1 is activated by H-, K- and N-Ras. It has 
been suggested that proliferation in non-trans formed cells may be controlled 
primarily by N-Ras, but most studies have employed H- or K-Ras (Hamilton et al, 
1998). Although Raf-1 also interacts with Rapl, the function of this interaction is 
uncertain, as no increase in activity is seen. On the other hand, B-Raf is activated by 
both Ras and Rapl. In neuronal model systems such as pheochromocytoma (PC 12) 
cells, activation of B-Raf by Rapl may be the dominant mechanism (Vossler et al., 
1997; Zwartkruis et al； 1998). 
Ras activation can also be mediated by GPCRs through the heterotrimeric G 
proteins (Sugden et al., 1997). The active Ras recruits MAPKKK (Raf) to the plasma 
membrane where Raf becomes activated. Active Raf then phosphorylates and 
activates the MAPKK (MEK), which in turn activates ERKl/2. The chain of events 
leading to ERK 1/2 activation takes place within the cytoplasm (Brunet et al., 1997). 
ERK 1/2 is the only member of the cascade to be translocated into the nucleus, which 
enables ERK 1/2 to activate nuclear transcriptional factors such as Elkl for the 
induction of c-fos gene expression (Treisman, 1996). A summary of the ERK 
cascade is shown in Figure 1.4. 
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1.3.1.2 Stress-activated protein kinase (JNK and p38) cascades 
In 1994，two distinct MAPK modules were identified in mammalian cells: the 
p46/p54 isoforms of JNK (Derijard et ai, 1994; Kyriakis et ai, 1994) and the p38 
MAPK (Han et aL, 1994; Lee et al., 1994a; Rouse et al., 1994). The kinases JNK and 
p38 are collectively known as stress-activated protein kinases because of their 
activation by environmental stressors, including osmotic and heat shock (Cuenda et 
al., 1997; Galcheva-Gargova et al., 1994; Kyriakis et aL, 1994), stretch (Komuro et 
aL, 1996) or inflammatory cytokines (Han et aL, 1994; Kyriakis et al,, 1994). The 
upstream activators of both cascades have been identified and appear to be members 
of the Rho family of low molecular weight GTP-binding proteins, Rac and cdc42, 
and the serine/threonine kinase PAX (p21 Ras-activated kinase) (Brunei et aL, 1997). 
With respect to the JNK cascade, JNK is activated by two MAPKK modules, 
MKK4 (also called as JNKK or SEK) (Deacon et al., 1997) or MKK7 (Moriguchi et 
al., 1997; Wu et al., 1997; Yao et aL, 1997)，see Figure 1.3. Titration experiments 
have shown that MAPKKKs (MEKKl to MEKK4) activate MKK4 with greater 
potency than that observed using MEK as a substrate (Blank et al., 1996; Gerwins et 
al., 1997; Minden et al,, 1994; Takekawa et ai, 1997). MEKKl can bind directly to 
an N-terminal extension of MKK4, which allows its phosphorylation and activation 
by MEKKl. MEKK2, 3 and 4 have also been shown to activate MKK4 although 
whether these MEKKs have a similar mechanism of interaction with MKK4 has not 
been demonstrated (Hagemann et al., 2001). Moreover, MEKKl, 2 and 3 can also 
directly phosphorylate and activate MKK7 (Deacon et al., 1999; Hirai et al., 1998). 
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The involvement of MEKKs in p38 activation is less clear. The upstream 
activators of p38 are the MKK modules MKK3, 4 and 6, which directly 
phosphorylate p38 in vitro and in vivo (Derijard et ai, 1995; Han et aL, 1996; Han et 
al” 1997; Raingeaud et ai, 1995; Raingeaud et al., 1996). MKK3, which is shown 
potentially to be activated by MKKK (MEKKS) (Deacon et aL, 1997)，specifically 
phosphorylates and activates p38 kinase but does not phosphorylate the related JNK 
or ERK cascade (Derijard et aL, 1995). MKK4 phosphorylates and activates both the 
p38 and JNK cascades in vitro (Derijard et al,, 1995). MKK6 has been shown as a 
direct substrate for MKKKs (MEKK2 and 3) to phosphorylate and activate p38 
(Deacon et al., 1999). Recently, a novel MKKK termed TAKl (transforming growth 
factor-p-activating kinase) has been identified and reported to participate in 
phosphorylation of JNK (Yamaguchi et aL, 1995) and p38 (Moriguchi et aL, 1996) 
pathways through activation of MKK4 and MKK3/6 (Terada et al., 1999; Wang et 
a/., 2001). 
Like ERK 1/2，both JNK and p38 kinases phosphorylate and activate 
numerous substrates in vitro (Brunet et aL, 1997). JNK kinase activates the Jun, 
ATF2 and Elkl transcriptional factors, leading to induction of c-fos and c-jun gene 
expression (Derijard et al, 1994; Hibi et al., 1993; Kyriakis et al., 1994; Whitehurst 
et al, 1995). In a similar manner, p38 kinase is also able to phosphorylate and 
activate ATF2 and Elkl transcriptional factors (Raingeaud et al., 1996)，as well as 
the protein kinase MAPK-activated protein kinase-2 (MAPKAP kinase-2) (Rouse et 
al., 1994). Thus the stress-activated kinases can integrate extracellular stimuli and 
convert them into specific cellular responses to stress. 
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1.3.2 Activation of ERK1/2 through GPCRs 
Activation of the ERK 1/2 cascade by peptide growth factors such as epidermal 
growth factor (EGF) has been studied extensively (Pawson, 1995). The EGF 
receptors are single transmembrane domain proteins that possess intrinsic ligand-
stimulated tyrosine kinase activity. Upon ligand binding, these receptor tyrosine 
kinases (RTKs) dimerize and transphosphorylate on their cytoplasmic domain. The 
resulting phosphotyrosine residues serve as docking sites to recruit components of 
the mitogenic signaling complex to the receptor. The mechanism is summarized in 
Figure 1.4. 
As with the RTKs, activation of the ERK 1/2 cascade by GPCRs signaling has 
been reported recently for a broad array of ligands such as angiotensin II (Sadoshima 
et al., 1995) and thromboxane A2/prostaglandin H2 (Morinelli et al., 1994; Watanabe 
et al., 1995). 
Among the list of GPCRs that activate the MAPK pathway, receptors interact 
with distinct subsets of heterotrimeric G proteins, including the pertussis toxin 
(PTX)-insensitive Gq/11 and PTX-sensitive Gi and Go families. Gs-coupled 
receptors have also been reported to activate ERK 1/2 (Erhardt et al, 1995; Faure et 
al., 1994)，although activation of adenylyl cyclase opposes ERK 1/2 activation in 
many systems (Burgering et al.’ 1993; Cook et al., 1993). This diversity suggests that, 
in appropriate cell types, heterogeneous upstream signals generated by GPCRs must 
ultimately converge upon the ERK 1/2 pathway (Luttrell et al., 1997). 
Several principal approaches have been employed to identify the signaling 
molecules, which may be involved in the biochemical routes from a GPCR to MAPK. 
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For example, PTX and co-expression of specific GPy scavengers were used to decide 
whether Got- or GPy-subunits of Gi or Gq family G proteins are involved. Secondly, 
various specific protein kinase inhibitors were used to identify putatively-involved 
signaling mediators. Thirdly, over-expression of putative key signaling molecules 
was used to enhance the GPCR-induced activation of MAPK or of constitutively 
active mutant of protein kinase modules to imitate the effect evoked by GPCR 
stimulation. Finally, co-expression of dominant negative mutants of key signaling 
molecules was used to confirm the involvement of a signaling protein of interest 
(Liebmann, 2001). 
Since GPCR signals are transduced through heterotrimeric G proteins, it is 
useful to consider the mechanism whereby the different Got- and GPy-subunits 
communicate with the ERXl/2 cascade. The mechanism employed by each receptor 
is determined by the G protein(s) with which it interacts and the available effectors in 
a particular cell type (van Biesen et al., 1996). 
Gaq/11 coupled pathway 
The best-characterized effector of the PTX-insensitive Gq/11 family of G proteins is 
PLC. When activated, PLC hydrolyzes PEPz, yielding DAG and IP3. IP3 in turn 
mobilizes calcium from intracellular stores. Calcium and DAG together activate PKC 
(Hepler et al., 1993; Taylor et aL, 1991; Wu et al., 1992; Wu et aL, 1993a). 
Activated PKC regulates a broad array of cellular signals (Newton, 1995). Treatment 
of cells with tumor-promoting phorbol esters that directly activate PKC results in the 
potent activation of ERKl/2. The mechanism by which PKC activates the ERKl/2 
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cascade is not entirely understood, although it has been suggested that PKC directly 
phosphorylates and activates Raf in a Ras-independent manner (Fig. 1.5) (Kolch et 
al, 1993). 
ERKl/2 activation by Gq/11-coupled receptors is mostly insensitive to 
inhibition by the GPy-sequestrants pARKct and a-transducin (Faure et al., 1994; 
Hawes et al., 1995; Koch et al, 1993), indicating that the signal is mediated 
predominantly by the a-subunit of Gq/11 (van Biesen et al.’ 1996). 
Activation of Gq-coupled Ml muscarinic receptors stimulates ERK2 activity 
in COS-7 cells, as does expression of Gaq or treatment with the PKC activator 
phorbol ester (Crespo et al., 1994a). Thus, activation of the ERK cascade by Gq-
coupled receptors involves activation of PKC. The activation of ERKl/2 by coupling 
to Gq/11 appears to be mediated by two or more signaling pathways, either Ras-
dependent or Ras-independent. 
In COS-7 and CHO cells, the stimulation of ERKl/2 activity by Gq-coupled 
receptors occurs independently of Ras activation (Koch et al.’ 1994) and is 
insensitive to inhibition by a dominant negative mutant of Ras (Hawes et aL, 1995). 
However, Gq-mediated signals are inhibited by a dominant negative mutant of Raf, 
indicating that Gaq activates ERK through a PKC and Raf-dependent pathway 
(Hawes et aL, 1995). The down-regulation of PKC activity in CHO cells by chronic 
exposure to phorbol ester completely blocks Gq-mediated ERKl/2 activation, 
whereas Gi- and receptor tyrosine kinase-mediated signals are unaffected. These 
observations reveal a Gq-specific ERKl/2 activation involving the PLC-mediated 
activation of PKC and Raf, but not Ras (Hawes et al, 1995). 
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Another study on COS cells, however, reported that stimulation of PKC 
promotes Ras activation and the formation of Ras-Raf-1 complexes. The assembly of 
these complexes was thought to occur by a mechanism distinct from that initiated by 
receptor tyrosine kinase activation (Marais et aL, 1998). These disparities may be 
due to different regulatory mechanisms in the individual cell lines (Lowes et al., 
2002). 
A novel calcium-dependent protein tyrosine kinase, PYK2, which was cloned 
from human brain (Lev et aL, 1995) and is highly expressed only in cells of neuronal 
origin, can be activated either by PKC or elevated levels of intracellular calcium. 
Stimulation of Gq-coupled bradykinin receptors in PC 12 cells activates PYK2. The 
activated kinase in turn mediates Ras-dependent ERK activation through tyrosine-
phosphorylation of She and Shc-Grb2-Sosl complex formation. These observations 
define a Gq- and calcium-mediated ERK 1/2 cascade that requires the same 
intermediates as the GPy- and RTK-mediated pathways (van Biesen et aL, 1996). 
In cultured rat vascular smooth muscle cells, PTX-insensitive ERK activation 
through the endogenous angiotensin II receptor is blocked by intracellular calcium 
chelation (Eguchi et al., 1996). Interestingly, this calcium-dependent pathway is also 
completely blocked by the calmodulin inhibitor calmidizolium and the tyrosine 
kinase inhibitor genistein (Eguchi et al., 1996)， suggesting that a 
calcium/calmodulin-sensitive tyrosine kinase might play a role in the regulation of 
the ERK 1/2 cascade. Thus, the multiple mechanism of ERK 1/2 activation by Gq-
coupled receptors depends on the type of receptors involved and occurs in a cell-
specific manner. 
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Gai/o coupled pathway 
Ras-dependent activation of ERKl/2 through Gi-coupled receptors was initially 
described by three laboratories. The receptors for lysophosphatidic acid (LPA) and 
a-thrombin mediate activation of Ras (van Corven et al, 1993)，Raf-1 and ERKl/2 
(Howe et al., 1993). The signals are PTX-sensitive, indicating the involvement of a 
Gi/o protein. Stimulation of the a2A-adrenergic receptor, which is specifically 
coupled to Gi2 and Gi3, leads to rapid and transient activation of Ras and ERK2 in 
Rat-1 fibroblasts (Alblas et al, 1993). These responses are unrelated to inhibition of 
adenylyl cyclase and dissociable from PLC activation. Carbachol stimulation of Rat-
1 cells expressing the Gi-coupled muscarinic receptor (MzAchR) leads to the PTX-
sensitive activation of Ras, Raf, MEK and ERKl/2 (Winitz et al, 1993). 
The analogy to RTK signaling was strengthened by the finding that LPA-
mediated Ras and ERK activation is sensitive to inhibition by low concentrations of 
the tyrosine kinase inhibitor genistein (van Corven et al., 1993). Subsequent 
experiments revealed that LP A stimulation of Rat-1 cells increases tyrosine 
phosphorylation, activation of Ras and ERKl/2 (Hordijk et al., 1994). Thyrotropin-
releasing hormone (TRH) (Ohmichi et al., 1994), endothelin (Cazaubon et al., 1994), 
angiotensin II (Sadoshima et al.’ 1996)，thrombin (Chen et al., 1996), LP A, and (X2a-
adrenergic receptors (Touhara et al., 1995; van Biesen et al., 1995) stimulate tyrosine 
phosphorylation of the She adaptor protein and its subsequent association with Grb2, 
suggesting that RTK- and Gi-mediated ERKl/2 signals converge at or above the 
level ofShc-Grb2 interaction (van Biesen et al., 1996). 
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The mounting evidence that Gi-coupled receptors can mediate increases in 
tyrosine protein phosphorylation and Ras-dependent ERK 1/2 activation contrasts 
with the lack of effect on these pathways in cells expressing the activated GTPase-
deficient God mutant, gip2. Indeed, Gi-coupled receptor-mediated ERKl/2 activation 
is not attributable to known effectors of G proteins, such as inhibition of adenylyl 
cyclase, PLC activation, or modulation of ion channels (Alblas et al, 1993; van 
Corven et al, 1993). The resolution of this apparent paradox seems to reside in a 
novel signaling pathway regulated by GPy-subunits and will be discussed below. 
Gas coupled pathway 
Gs-coupled receptors may activate or inhibit ERKl/2 cascade, and do so in a cell-
specific manner. In COS-7 cells, stimulation with isoproterenol, a (3-adrenergic 
agonist, results in activation of PKA and ERKl/2 (Crespo et al., 1995). Similar 
results were reported for transiently expressed Gs-coupled lutropin receptors and 
constitutively activating Gs in these cells (Faure et al., 1994). 
However, cyclic AMP inhibits the activation of Raf-1, resulting in the 
inhibition of both growth factor-stimulated cell proliferation and ERKl/2 activation 
in rat adipocyes and human arterial smooth muscle cells (Sevetson et al., 1993; Wu 
et al, 1993b). Forskolin-treated NIH 3T3 fibroblast cells showed reduced activation 
of Raf, MEK and ERK2, but not Ras (Burgering et al, 1993; Cook et al.’ 1993; Li et 
al., 1995). Increased cyclic AMP levels are associated with increased 
phosphorylation of Raf-1 by PKA on Ser-43 consensus site with the Raf-1 regulatory 
domain just upstream of the Ras-binding domain (Wu et al, 1993b). This 
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phosphorylation reduces the affinity with which Raf-1 binds to Ras, both in vitro and 
in vivo, suggesting that it is responsible for cyclic AMP-mediated inhibition of Raf-1 
(Wu et al., 1993b). However, the observation that Raf kinase mutants lacking Ser-43 
were still susceptible to cyclic AMP inhibition indicated that PKA phosphorylation 
can, in addition, directly suppress the catalytic activity of Raf-1 (Mischak et al., 
1996). ERKl/2 activity in Ras-transformed Rat-1 fibroblasts is inhibited by treatment 
with 8-bromo-cAMP, consistent with cyclic AMP-mediated inhibition at a step 
downstream of Ras (Sevetson et al., 1993). 
However, growth factors and cyclic AMP have antagonistic effects on 
fibroblasts, and both nerve growth factor (NGF) and cyclic AMP can induce 
neuronal differentiation of PC 12 cells (Greene et al., 1976; Gunning et al” 1981; 
Richter-Landsberg et aL, 1986). Moreover, combined treatment with NGF with 
cyclic AMP has synergistic effects on neurite formation (Gunning et al., 1981; 
Richter-Landsberg et al, 1986). The induction of differentiation by NGF is mediated 
by Ras-Raf-mediated ERKl/2 cascade, as dominant inhibitory mutants of Ras and 
MEK interfere with NGF-induced differentiation (Cowley et al., 1994; Szeberenyi et 
aL, 1990) whereas constitutively active mutants of Ras, Raf and MEK are themselves 
sufficient to induce differentiation (Bar-Sagi et aL, 1985; Cowley et al., 1994; Noda 
et al” 1985; Troppmair et al., 1992). In contrast to NGF, the mechanism by which 
cyclic AMP induces differentiation is unclear. However, it appears that in contrast to 
the situation in fibroblasts, the stimulation of ERKl/2 by NGF in PC12 cells is not 
inhibited by cyclic AMP (Frodin et al., 1994; Vaillancourt et al., 1994). 
Differentiation requires sustained ERKl/2 activation and ERKl/2 nuclear 
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translocation, which mainly appears to be mediated by cyclic AMP through 
stimulation ofMEK (Yao et al, 1998). 
One of the major differences between the ERKl/2 cascades in PC 12 cells and 
Rat-1 fibroblasts is the presence of B-Raf in PC 12 cells, in which it appears to be the 
major MEK activator (Hunter, 1995; Moodie et al., 1994). In PC12 cells, cyclic 
AMP was reported to shut off Raf-1 but stimulate ERK 1/2 through the activation of 
B-Raf by the Ras-related G protein Rapl (Grewal et al., 2000). Rapl was originally 
isolated as a suppressor of Ras transformation, probably because it can bind to and 
sequester Raf-1 in an inactive complex when overexpressed. In contrast, Rapl can 
bind to and activate B-Raf (Ohtsuka et aL, 1996). Interestingly, cyclic AMP and 
NGF are two of the growth factors among the physiological activators of Rapl 
(Vossler et aL, 1997). The method by which cyclic AMP activates Rapl is still not 
clear. It has been shown that PKA can phosphorylate Rapl, and this was assumed to 
provide the underlying molecular mechanism for activation (Houslay et al., 2000). 
However, more recently cyclic AMP-activated GDP/GTP exchange factors (GEF) 
have been identified (de Rooij et al” 1998; Kawasaki et al., 1998). These possess 
both a cyclic AMP binding domain and GTPase exchange factor domains, which 
serve to activate Rap without requirement of PKA. It may be that both PKA-
dependent and PKA-independent pathways can allow Rap 1 activation and that these 
are selected in a cell-type specific manner (Houslay et al, 2000). 
The PKA consensus site found in the regulatory domain of Raf-1 is not 
present in B-Raf (Sithanandam et al.’ 1990)，so B-Raf might be expected to be 
resistant to inhibition by cyclic AMP. It was demonstrated that the effect of cyclic 
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AMP on B-Raf is dependent upon growth conditions for both PC 12 cells and 
transfected B-Raf-expressing Rat-1 fibroblasts (Erhardt et al., 1995). While Raf-1 is 
effectively inhibited by cyclic AMP, B-Raf is resistant to inhibition by cyclic AMP 
under normal growth conditions. Thus, it appears that Raf-1 and B-Raf are 
differentially regulated by cyclic AMP and that the relative insensitivity of B-Raf to 
cyclic AMP contributes to cyclic AMP stimulation of the ERKl/2 pathway in PC 12 
cells. However, the expression of B-Raf in Rat-1 cells was not sufficient to cause 
ERKl/2 activation by cyclic AMP alone, whereas cyclic AMP itself was able to 
stimulate ERKl/2 in PC12 cells. This stimulation of ERKl/2 by cyclic AMP in PC12 
cells was Ras-dependent, indicating that cell-specific factors acting upstream of Ras 
are also required for the GPCR-mediated-cyclic AMP stimulation of the ERKl/2 
cascade (Erhardt et aL, 1995). Evidence from other cell systems also suggests that 
the expression of B-Raf determines whether cyclic AMP inhibits or activates 
ERKl/2 cascade (Gao et al., 1999; Seidel et al, 1999). 
GPy-coupled pathway 
As an approach to explore the mechanism of ERKl/2 activation by GPCRs, several 
laboratories have used the transient co-expression of an epitope-tagged form of 
ERKl/2 together with GPCRs in readily transfectable cell lines, such as COS-7 cells 
(Crespo et al, 1994b; Faure et al., 1994; Koch et aL, 1994). In this cellular setting, it 
was observed that ERKl/2 activation through the PTX-sensitive Gi-coupled m2 
muscarinic receptors and PTX-insensitive Gq-coupled ml muscarinic receptors was 
attenuated by coexpression of the a-subunit of transducin, which acts to sequester 
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Gpy-subunits released upon stimulation from endogenous G proteins (Crespo et al., 
1994b). With the use of carboxy-terminal fragment of the GPy-sequestrants pARKl 
enzyme (PARKct), expression of (3ARKct significantly inhibits ERKl/2 activation 
by the Gi-coupled ocsaAR and MiAchR in transiently transfected COS-7 cells (Koch 
et al., 1994). Similarly, PARKct overexpression antagonizes activation of both Ras 
and ERKl/2 through endogenous LPA receptors. Since a constitutively active mutant 
of Gai2 did not increase ERK activity in COS-7 cells (Faure et a!., 1994)，the 
mitogenic signals mediated by Gi-coupled receptors appear to be entirely dependent 
on a Gpy-mediated pathway. Furthermore, transient transfection of GP and Gy cDNA 
into COS-7 cells, did not stimulate ERK activity, indicating that GPy-subunits alone 
are not sufficient for ERK activation (Crespo et al., 1994b; Faure et al., 1994); nor 
do isoprenylation deficient mutants of Gy-subunits, even in combination with Gp-
subunits (Crespo et al., 1994b). 
Coexpression of combinations of GP and Gy cDNAs in COS-7 cells revealed 
that those pairs known to form functional Gpy-complex (plyl , P1y2, plyS, 口2丫2) 
(Iniguez-Lluhi et al., 1992; Pronin et al., 1992; Schmidt et al., 1992; Ueda et al., 
1994) stimulated both ERKl and phosphatidylinositol (PI) hydrolysis (Hawes et aL, 
1995). Both processes were abrogated by co-expressed pARKct peptide. Dominant 
negative mutants of Ras and Raf specifically inhibited GPy-mediated ERK activation, 
without affecting PI hydrolysis. Thus expression of Gpy-subunits was sufficient to 
mimic Gi-coupled receptor mediated activation of Ras, Raf and ERK (Alblas et aL, 
1993; van Corven et al, 1993; Winitz et al., 1993). 
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Using a variety of experimental approaches, it was shown that stimulation of 
ERKI/2 by co-expressed Py-dimers required neither PLC-P nor PKC activation, but 
was blocked by molecules inhibiting Ras function (Crespo et al, 1994a; Koch et al, 
1994). Furthermore, Py-subunits were later shown to be sufficient to induce the 
accumulation of Ras in its GTP-bound form (Koch et al,, 1994). Taken together, 
these findings indicate that signaling from GPCR to ERKl/2 cascade involves py-
heterodimers acting in a Ras-dependent manner (Gutkind, 1998). 
The idea that tyrosine kinases might mediate the activation of ERK 1/2 by 
GPy-subunits came from the observation that tyrosine kinase inhibitors (genistein 
and herbimycin A) diminishes Gpy-stimulated ERKl/2 activation by LPA in a dose-
dependent manner, with no effect on Gp丫-stimulated inositol phosphate production 
(Hawes et al., 1995). The tyrosine kinase inhibitors had no effect on ERK activation 
mediated by a constitutively active mutant of Ras, indicating that the inhibitor-
sensitive step lies upstream of Ras. Thus, activation of PLC by GPy-subunits is not 
sufficient to account for activation of the ERKl/2 pathway (Hordijk et al., 1994). 
More recent studies demonstrate that tyrosine kinase-mediated activation of ERKl/2 
leads to the rapid phosphorylation of the adaptor protein She on tyrosine residues and 
the formation of Shc-Grb2 complexes (Sadoshima et al, 1996; van Biesen et aL, 
1995). Furthermore, Src, or Src-like kinases, mediate the Gp 丫-induced 
phosphorylation of She, the recruitment of Grb2 and SOS, and the subsequent 
stimulation of the Ras-dependent ERKl/2 cascade (Luttrell et al, 1996). Extending 
these observations, recent studies have implicated other non-receptor tyrosine 
kinases in signaling from GPCRs to ERKl/2. These include several Src-like kinases 
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such as Fyn, Lyn, Yes and the more distantly related Syk (Ptasznik et ai, 1995; Wan 
et aL, 1996)，and a novel calcium- and PKC-dependent protein tyrosine kinase Pyk2 
(Delia Rocca et aL, 1997; Dikic et al.’ 1996; Lev et al., 1995). These findings 
suggest that GPCRs and tyrosine kinases can induce Ras activation through 
convergent signaling pathways as shown in Figure 1.6. 
Additional signaling molecules have been recently shown to connect GPCRs 
and Gpy-subunits to the Ras-dependent ERK 1/2 cascade. These include the protein 
tyrosine phosphatase SH-PTPl (Gaits et al,, 1996)，Ras-GRF (distinct Ras guanine-
nucleotide exchange factor expressed in neuronal cells) (Mattingly et ai, 1996) and 
PIBKy (a novel phosphatidylinositol 3-kinase isotype) (Lopez-Ilasaca et aL, 1997). 
Ras-GRF was found to be enhanced in response to GPCR stimulation or upon co-
expression of Gpy-subunits by a still unclear mechanism (Mattingly et al., 1996). In 
the case of PI3Ky, the observation that wortmannin, a PI3K inhibitor, can diminish 
ERKI/2 activation by GPCRs (Hawes et al., 1996)，provided the first indication of a 
role for this lipid kinase in GPCR signaling to the ERKl/2 cascade. The PIBKy is not 
stimulated by tyrosine phosphorylation, but instead is activated upon direct physical 
interaction with Gfy complexes (Stoyanov et al, 1995). This PBKy was found to act 
downstream from Gpy and upstream of Src-like kinases and She, Grb2, SOS and Ras, 
thus suggesting a potential mechanism whereby heterotrimeric G proteins can 
regulate non-receptor tyrosine kinases and, in turn, control the ERKl/2 cascade 
(Lopez-Ilasaca et al, 1997). 
““ Page 46 
Chapter 1 Introduction 
PKC-mediated pathway 
ERKl/2 activation by GPCRs in a Ras-independent manner has also reported and 
one such example may involve direct phosphorylation of Raf by PKC as discussed 
above, this results in increased Raf phosphorylation of MEK (Macdonald et al., 
1993). In addition, PKC activation appears not to induce Ras-GTP accumulation in 
the vast majority of cell types (Bos et al, 1995), however, it activates ERKl/2 in a 
Ras-dependent manner in several cellular settings (Burgering et al, 1995; Hawes et 
al., 1995; Thomas et al., 1992). As Ras alone is not sufficient to activate Raf fully in 
vitro (Macdonald et al., 1993) or when co-expressed in Sf9 insect cells (Kikuchi et 
al, 1994)，it is possible that PKC might act on the ERKl/2 cascade by facilitating the 
full activation of Raf upon binding to Ras (Burgering et al, 1995). Thus, PKC 
activation would then be expected to play a critical role in MAPK stimulation under 
conditions of sub-maximal activation of Ras by cell surface receptors. This might 
help explain some conflicting observations regarding Gq-coupled receptors, as these 
receptors can activate ERKl/2 in a PKC-dependent (Hawes et al, 1995), fully PKC-
independent (Charlesworth et al, 1997)，or partially PKC-dependent (Crespo et al., 
1994a) manner. 
Although additional molecules may participate in ERKl/2 activation by 
GPCRs, many of the likely candidates may have already been identified. 
Interestingly, several of the proteins described above exhibit a very restricted tissue 
distribution (Grewal et al, 2000; Lev et al., 1995; Stoyanov et al, 1995). Thus, the 
nature of the molecules linking GPCR to ERKl/2 activation is expected to depend on 
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the repertoire of signaling molecules available in each particular cellular system 
(Gutkind, 1998). 
The aim of my study was to examine the IP-receptors to regulate the ERKl/2 
cascade by coupling to different G proteins in order to predict the antimitogenic 
properties of prostacyclin. Transent transfection system in CHO cells and neuronal 
cell lines endogenously expressing IP-receptors were used to define any crosstalk 
between Gs- and Gq-mediated pathways. Two different methods were used to assay 
the ERKl/2 activity in different cells systems based on their transfection efficiencies 
of different cell lines. By coupling to different G proteins activating different 
effectors in the cells to regulate ERK cascade, we can predict different G proteins are 
responsible for the mitogenic or anti-mitogenic effect of prostacyclin. 
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Figure 1.3 Summary of MAPK signal transduction cascades in a schematic cross-
section though a cell (Hagemann et al., 2001; Widegren et al., 2001). 
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Figure 1.4 Schematic representation of receptor-mediated activation of the ERKl/2 
cascade (van Biesen et aL, 1996). 
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Figure 1.5 ERXl/2 activation by Gq/11 receptors such as muscarinic acetylcholine 
subtype 1 (MlAchR) and aieadrenergic receptor (aiBAR)(van Biesen et al., 1996) 
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Figure 1.6 Proposed ERKl/2 activation by GPy-subunit from GPCRs such as 
lysophatidic acid receptor (LPAR) and a2A-adrenergic receptor (OCZAAR) (van Biesen 
etal, 1996). 
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Chapter 2 
Materials and solutions 
2.1 MATERIALS 
Aqueous solutions were prepared in ultra-pure water (i.e. double distilled, deionised 
water). 
8-[^H]-adenme (specific activity 27 Ci/mmol) was purchased from Amersham and 
stored at 4°C. 
30% Acrylamide (Sigma) 
Alumina (alumina, neutral type WN-3, Sigma) 
Ammonia solution (25%, BDH) 
Ammonium formate (Sigma) 
Ammonium persulfate (APS, Sigma) was dissolved in ultra-pure water at 0.1 g/ml 
and stored at -20°C. 
Anti-rabbit IgG, HRP-linked antibody (Cell Signaling) 
Aprotinin (Sigma) was dissolved in ultra-pure water at 2 mg/ml and stored at -20�C. 
ATP (adenosine 5'-triphosphate, Sigma) was prepared fresh on day of assay. 
Bovine serum albumin (BSA, Sigma) was dissolved in 0.5 M NaOH at 1 mg/ml and 
stored at 4°C. 
Bradykinin (Sigma) was dissolved in ultra-pure water at 1 mM and stored at -20°C. 
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Bromophenol blue (Sigma) 
Calcium chloride (Sigma) 
5X Cell Lysis Buffer (CLB, Promega) 
Cicaprost (gift from Schering AG, Germany) was supplied in aqueous solution or 
prepared as a 1 mM stock solution in ultra-pure water and stored at -20°C. 
Dimethyl sulphoxide (DMSO, Sigma) 
1,4-DithiothreitoI (DTT, Pharmacia Biotech) 
Dowex (AG50W-X4 resin, formate form, 200-400 mesh, Bio-Rad) 
Dowex (AG 1-X8 resin, formate form, 100-200 mesh, Bio-Rad) 
Dulbecco's Modified Eagle Medium (DMEM, Gibco) 
ECL Western blotting reagents (Amersham) 
Ethanol (absolute, Merck) 
EDTA (Ethylenediamine-tetraacetic acid, Sigma) 
Fetal bovine serum (FBS, Sigma) 
Formic acid (BDH) 
Forskolin (Sigma) was dissolved in absolute ethanol at 10 mM and stored at -20°C. 
GiiQL cDNA (a gift from Dr. Y.H. Wong, HKUST) was cloned in the pcDNAl.l 
expression vector. 




H-89 (Biomol) was dissolved in DMSO at 10 mM and stored at -20�C. 
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Ham's nutrient mixture F-12 (Sigma) 
HAT Supplement (Gibco) was reconstituted with 10 ml sterile ultra-pure water and 
stored at 4°C. 
Hepes (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid], Sigma) 
HiSafe3 scintillant (Pharmacia Biotech) 
Human neuroblastoma cell line (SK-N-SH, a gift from Dr. Y.H. Wong, HKUST) 
Human prostacyclin receptor (hIP) cDNA (a gift from Dr. Kobayashi, Kyoto 
University) was subcloned into the pcDNA3.1 expression vector by Kevin Chow. 
Hydrochloric acid (12.1 M, Merck) 
IBMX (3-isobutyl-1 -methy-xanthine, Sigma) was dissolved in DMSO at 100 mM 
and stored at -20°C. 
Imidazole (Sigma) 
Indomethacin (Sigma) was dissolved in absolute ethanol at 10 mM and stored at 
- 2 0 � C . 
Leupeptin (Sigma) was dissolved in ultra-pure water at 2 mM and stored at -20°C. 
L-Glutamine (Gibco) 
Lipofectamine (Invitrogen) 
Lithium chloride (Sigma) was prepared in ultra-pure water at 1 mM and stored at 
4�C. 
Luciferase Assay Buffer (Promega) 
Luciferase Assay Buffer II (Promega) 
Luciferase Assay Reagent (LAR, Promega) 
Luciferase Assay Reagent II (LAR II，Promega) 
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Magnesium chloride (Sigma) 
Mouse prostacyclin receptor (mlP) cDNA (a gift from Dr. Kobayashi, Kyoto 
University) was cloned in pCMX expression vector. 
Afyo-inositol-[2-^H(N)] (specific activity 22.2 Ci/mmol) was purchased from NEN 
and stored at 4°C. 
n-butanol (Sigma) was saturated in 100 ml ultra-pure water and stored at room 
temperature. 
Non-fat milk powder (Nestle) 
Opti-mem I (Gibco) 
p44/42 MAP kinase (Thr202/Tyr204) antibody (Cell Signaling) 
5X Passive Lysis Buffer (PLB, Promega) 
pcDNAl.l vector DNA (Invitrogen, San Diego, CA) 
PD98059 (Biomol) was dissolved in DMSO at 10 mM and stored at -20°C. 
Penicillin/Streptomycin solution (Sigma) was reconstituted with 20 ml sterile ultra-
pure water and stored at 4°C. 
PMA (Phorbol 12-myristate 13-acetate, Sigma) was dissolved in DMSO at 10 mM 
and stored in aliquots, in the dark at -20°C. 
PMSF (Phenylmethylsulfonyl fluoride, Sigma) 
Phospho-p44/42 MAP kinase (Thr202/Tyr204) antibody (Cell Signaling) 
Phospho-SAPK/JNK (Thr 183/Tyrl85) antibody (Cell Signaling) 
Ponceau S (Sigma) 
Potasssium chloride (KCl, Sigma) 
Potassium dihydrogen phosphate (KH2PO4, Merck) 
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Potassium hydroxide (KOH, Sigma) 
Rat/mouse neuroblastoma/glioma cell line (NG108-15, a gift from Prof. Fiscus, 
CUHK)) 
Rp-cAMPS (Biomol) was dissolved in ultra-pure water at 10 mM and stored at 
-20°C. 
RPMI-1640 (Sigma) 
Stop & Glo buffer (Promega) 
SOX Stop & Glo Reagent (Promega) 
Sodium bicarbonate (NaHCOs, Sigma) 
Sodium chloride (NaCl, Sigma) 
Sodium dodecyl sulfate (SDS, Bio-Rad) 
Sodium hydroxide (Na OH, NA Chemicals) 
Sodium Orthovanadate (NasC^V，Sigma) was dissolved in ultra-pure water at 0.1 
M and stored at -20°C. 
Sodium Pyrophosphate (N2nOi?2, Sigma) 
Staurosporine (Biomol) was dissolved in DMSO at 10 mM and stored at -20°C. 
TEMED (Sigma) 
Trichloroacetic Acid (TCA, Sigma) was dissolved in ultra-pure water to a 
concentration of 5% (w/v) and stored at 4°C. 
Triton X-100 (Sigma) 
Trizma® base (Tris [hydroxymethyl] amino-methane, Sigma) 
Trypan blue (Sigma) 
0.25% Trypsin/EDTA (Sigma) 
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Tween 20 (Pharmacia Biotech) 
U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene, Biomol) was 
dissolved in DMSO at 20 mM and stored at 一20°C. 
All disposable 56.7 cm� petri dishes were supplied by Nunclon. Six- and 24-well 
plates were supplied by Coming. All the apparatus used in western blotting 
experiments was supplied by Bio-Rad. 
2.2 CULTURE MEDIA, BUFFER AND SOLUTIONS 
2.2.1 Culture media 
Dulbecco's modified Eagles Medium (DMEM) 
Dulbecco's modified Eagles Medium (Gibco) was purchased as liquid medium and 
stored at 4�C. Aminopterin (0.4 |iM), L-glutamine (2 mM), penicillin (100 units/ml), 
sodium hypoxanthine (0.1 mM), streptomycin (100 |ig/ml), thymidine (16 \M) and 
fetal bovine serum (6% v/v) were added to each 100 ml medium when required and 
stored at 4°C. 
Ham's Nutrient Mixture F-12 
Ham's Nutrient Mixture F-12 (Sigma) was reconstituted with 1000 ml ultra-pure 
water, and supplemented with NaHCOs (1.18 g/L). The pH was adjusted to 6.8 with 
1 M HCl and filter-sterilized through a 0.22 \xm filter into 1000 ml bottles to give a 
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final pH of 7.0, stored at 4°C. Penicillin (100 units/ml), streptomycin (100 |ig/ml) 
and fetal bovine serum (10% v/v) were added when required and stored at 4°C. 
RPMI-1640 
RPMI-1640 (Sigma) was reconstituted with 1000 ml ultra-pure water, and 
supplemented with NaHCOs (2.0 g/L). The pH was adjusted to 6.8 with 1 M HCl and 
filter-sterilized through a 0.22 i^m filter into 1000 ml bottles to give a final pH of 7.0, 
and stored at 4�C. Penicillin (100 units/ml), streptomycin (100 ng/ml) and fetal 
bovine serum (10% v/v) were added when required and stored at 4°C. 
2.2.2 Buffers 
Dulbecco's PBS (PBSA: Ca2+/Mg2+ free) was prepared with the following ACS 
reagents supplied by Sigma: KCl (2.7 mM), KH2PO4 (1.4 mM), NaCl (137 mM) and 
Na2HP04 (8.1 mM) in ultra-pure water. The pH was adjusted to 7.5 with 1 M NaOH 
and the solution was filter-sterilized to give final pH of 7.4 and stored at 4°C. 
HEPES buffer saline (HBS) was prepared with the following ACS reagents 
supplied by Sigma: CaClz.^HjO (2.2 mM), Hepes (15 mM), KCl (4.7 mM), KH2PO4 
(1.2 mM), MgCl2.6H20 (1.2 mM), NaCl (140 mM) in ultra-pure water. The pH was 
adjusted to 7.5 with 1 M NaOH and the solution was filter sterilized giving a final pH 
of 7.4 and stored at 4°C. Glucose (11 mM) was added on the day of experiment. 
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Lysis buffer was prepared with the following reagents by Sigma: Trizma® base (50 
mM), NaCl (100 mM), EDTA (5 mM), Na^OyP! (67 mM) and Triton X-100 (0.01%) 
in ultra-pure water. The pH was adjusted to 7.5 with NaOH and stored at 4°C. 
Immediately prior to the experiment, PMSF (0.2 mM), NajC^V (0.2 mM), DTT (1 
mM), leupeptin (4 |iM) and aprotinin (4 |ig/ml) were added before use. 
IX Passive lysis buffer (Promega) was prepared by mixing 5X PLB (5 ml) with 
ultra-pure water (20 ml) and stored at 4°C. 
6X sample buffer was prepared by dissolving bromophenol blue (8 mg), SDS (4 g)， 
DTT (3.72 g) and glycerol (12 ml) with 28 ml stacking buffer. The buffer was stored 
in aliquots at -20°C. 
Separating buffer was prepared by dissolving Trizma® base (90.8 g) with 400 ml 
ultra-pure water and the pH was adjusted to 8.8 with 4 M HCl. The volume of the 
buffer was made up to 500 ml and stored at 4°C. 
Stacking buffer was prepared by dissolving Trizma® base (30.2 g) with 400 ml 
ultra-pure water and the pH was adjusted to 6.8 with 4 M HCl. The volume of the 
buffer was made up to 500 ml and stored at 4°C. 
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lOX running buffer and lOX transfer buffer was prepared by dissolving Trizma® 
base (60 g) and glycine (288 g) with 1800 ml ultra-pure water. The volume of the 
buffer was made up to 2 L and stored at room temperature. 
IX running buffer was prepared by mixing lOX running buffer (200 ml) and 20 ml 
of 10% SDS. The volume of the buffer was made up to 2 L with ultra-pure water and 
stored at room temperature. 
IX transfer buffer was prepared by mixing lOX transfer buffer (600 ml) and 
absolute ethanol (900 ml). The volume of the buffer was made up to 6 L with ultra-
pure water and stored at room temperature. 
lOX tris buffer saline (TBS) was prepared by dissolving Trizma® base (121.11 g), 
Tween 20 (10 g) and NaCl (175.32 g) with 600 ml ultra-pure water and the pH was 
adjusted to 7.5 with 4 M HCl. The volume of the buffer was made up to 2 L and 
stored at room temperature. 
IX tris buffer saline (TBS) was prepared by mixing lOX TBS (100 ml) with ultra-
pure water (900 ml) and stored at room temperature. 
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2.2.3 Solutions 
5% Trichloroacetic acid (TCA) was prepared by dissolving 50 g/L TCA in ultra-
pure water. The solution was stored at 4°C. On the day of experiment, ATP (1 mM) 
was added to 5% TCA before use. 
IM formic acid was prepared by adding 37.73 nl 26.5 M formic acid stock solution 
to ultra-pure water and the colume was made up to 1000 ml. The solution was stored 
at room temperature. 
20 mM formic acid was prepared by adding 20 ml 1 M formic acid to ultra-pure 
water and the volume was made up to 1000 ml. The solution was stored at 4 °C. 
4 M ammonium formate was prepared by dissolving 252.24 g/L ammonium 
formate in ultre-pure water. The solution was stored at room temperature. 
2 M ammonium formate/0.1 M formic acid was prepared by mixing 1000 ml of 4 
M ammonium formate with 200 ml 1 M formic acid. The solution was made up to 
2000 ml with ultra-pure water. The solution was stored at room temperature. 
0.05% ammonia was prepared by adding 2 ml 25% ammonia solution to ultra-pure 
water and the volume was made up to 1000 ml. The solution was stored at room 
temperature. 
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10% SDS was prepared by dissolving SDS (10 g) with ultra-pure water (80 ml). The 
volume of the solution was made up to 100 ml and stored at room temperature. 
Imidazole (500 mM) was prepared by dissolving 52.25 g/L imidazole in ultra-pure 
water and the pH was adjusted to 7.5 with 1 M NaOH. This stock solution was 
diluted to 0.1 M with ultra-pure water before use. The solution was stored at room 
temperature. 
Ponceau S solution was prepared by dissolving Ponceau S (3 g) and TCA (20 g) 
with ultra-pure water. The volume of the solution was made up to 1 L and stored at 
room temperature. 
Blocking solution was prepared by dissolving non-fat milk powder (50 g) with IX 
TBS. The volume of the solution was made up to 1 L and stored at 4°C. 
Luciferase assay reagent (LAR) was reconstituted with 10 ml luciferase assay 
buffer, and aliquoted into polypropylene tubes immediately prior to the experiment 
or stored at -20°C for up to 4 weeks. 
Luciferase assay reagent II (LAR) was reconstituted with 10 ml luciferase assay 
buffer II，and aliquoted into polypropylene tubes immediately prior to the experiment 
or stored at -20°C for up to 4 weeks. 
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Stop & Glo reagent was prepared by adding SOX Stop & Glo reagent (200 |il) to 
Stop & Glo Buffer (10 ml), and aliquoted into polypropylene tubes immediately prior 
to the experiment or stored at -20°C for up to 4 weeks. 
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Chapter 3 
Methods 
3.1 MAINTENANCE OF CELL LINES 
3.1.1 Chinese Hamster ovary (CHO) cells 
CHO cells were cultured in F-12 medium supplemented with 10% FBS, 100 units/ml 
penicillin and 100 \ig/m\ streptomycin in a humidified atmosphere of 5% C02/95% 
air at 37�C. ells were passaged twice a week at approximately 80% confluency. The 
medium was removed from the 56.7 cm^ petri dish and rinsed with 10 ml PBS A. The 
PBS A was then aspirated and 1.5 ml trypsin-EDTA was added to the dish for 5 to 10 
min at room temperature. The cells were observed under a microscope and when 
rounded up, the dish was tapped to dislodge the cells. When the cells were 
completely detached from the dish, 10 ml complete medium was added to neutralize 
the trypsin. The cell suspension (0.66 ml) was added to a new dish with 14 ml culture 
medium (split ratio 1:17). When counting cells, 10 of cell suspension was 
transferred to a hemocytometer slide and counted under the microscope. 
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3.1.2 Human neuroblastoma (SK-N-SH) cells 
SK-N-SH cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 
100 units/ml penicillin and 100 ng/ml streptomycin in a humidified atmosphere of 
5% C02/95% air at 37�C. ells were passaged once a week at approximately 80% 
confluency. The medium was removed from the 56.7 cm^ petri dish and rinsed with 
10 ml PBS A. The PBS A was then aspirated and 1.5 ml trypsin-EDTA was added to 
the dish for 5 to 10 min at room temperature. The cells were observed under a 
microscope and when rounded up, the dish was tapped to dislodge the cells. When 
the cells were completely detached from the dish, 10 ml complete medium was 
added to the dish. The cell suspension (1 ml) was added to a new dish with 10 ml 
culture medium (split ratio 1:11.5). When counting cells, 10 |il of cell suspension 
was transferred to a hemocytometer slide and counted under the microscope. 
3.1.3 Rat/mouse neuroblastoma/glioma hybrid (NG108-15) cells 
NG108-15 cells were cultured in DMEM medium supplemented with 6% FBS, O.l 
mM sodium hypoxanthine, 0.4 \xU aminopterin, 16 |iM thymidine, 2 mM L-
glutamine, 100 units/ml penicillin and 100 |ag/ml streptomycin in a humidified 
atmosphere of 5% C02/95% air at 37�C. ells were passaged twice a week at 
approximately 80% confluency. The medium was removed from the 56.7 cm: petri 
dish and rinsed with 10 ml PBS A. The PBS A was then aspirated and 10 ml medium 
was added to the dish for 5 to 10 rriin at room temperature. The cells were observed 
under a microscope and when cells rounded up, the dish was tapped to dislodge the 
cells. The cell suspension (1 ml) was added to a new dish with 14 ml culture medium 
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(split ratio 1:10). When counting cells, 10 |il of cell suspension was transferred into 
hemocytometer slide and counted under the microscope. 
3.2 TRANSIENT TRANSFECTION OF MAMMALIAN CELLS 
Calcium phosphate, lipofection and electroporation are the most common means by 
which DNA is introduced into cells. DNA introduced into cultured cells need not 
integrate into cellular chromatin in order to be expressed. The expression of the 
introduced DNA can be monitored as early as 12 h and as late as 72 h after 
transfection (Gorman, 1985). Assays performed within this time interval are referred 
to as transient transfection experiments (Alam et al., 1990). 
Cells were grown in culture plates and transfected at approximately 80% 
confluency using lipofectAMINE liposome reagent and Opti-mem I reduced serum 
medium according to manufacturer's instructions. For each well of a 6-well plate, the 
required receptor DNA was mixed with Opti-mem I medium and the volume made 
up to 40 jil. In addition, lipofectAMINE liposome reagent was mixed with Opti-mem 
I medium and made up to 40 \xl The two solutions were then combined to form the 
transfection cocktail and allowed to stand at room temperature for 20 min with the 
ratio of DNA and lipofectAMINE liposome reagent of 1 ^g to 5 The transfection 
cocktail was then made up to 1 ml with Opti-mem I medium and added to the well 
for 5 h incubation at 37°C. The transfection cocktail was then removed and cells 
were incubated with 2 ml complete medium. All transfected cells (mEP-CHO and 
hIP-CHO) were assayed 48 h post-transfection. 
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3.3 MEASUREMENT OF ERK ACTIVITY 
3.3.1 PathDetect® Elk1 trans-Reporting System 
3.3.1.1 Introduction 
Reporter gene systems have been used to study receptor-mediated signal transduction 
events (Alam et al, 1990). The reporter vector is a plasmid typically consisting of a 
natural promoter element, or a synthetic promoter containing multiple copies of a 
specific transcriptional factor binding site placed upstream of a minimal promoter 
element, used to promote the expression of a readily detectable reporter protein by a 
reporter gene (Stables et al,, 1999). In general, reporter vectors share certain 
properties (Fig. 3.1) such as a prokaryotic origin of replication and an antibiotic 
resistance gene (Alam et al” 1990). These features permit propagation and selection 
of the vector in Escherichia coli. In addition, these vectors generally possess a 
eukaryotic polyadenylation (poly (A)) signal site and an intron, either intrinsic to the 
reporter gene or derived from a heterologous source. Poly (A) signals cause the 
termination of transcription by RNA polymerase II and signal the addition of 
approximately 200-250 adenosine residues to the 3，end of the RNA transcript 
(Proudfoot, 1991). Poly (A) has been shown to enhance RNA stability and 
translation (Bernstein et al, 1989; Jackson et al., 1990). The presence of an intron is 
necessary for efficient production of some mature cytoplasmic RNAs (Sambrook et 
al., 1989). Therefore, introns are often included in expression vectors. 
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The reporter enzyme typically has a unique activity or structure to enable it to 
be distinguished from other proteins inside cells. The choice of reporter gene is often 
an enzyme using colorimetric, fluorescent or luminescent assay of the activity of the 
protein product such as luciferase and P-gal. For example, firefly (Photinus pyralis) 
luciferase gene has been cloned (de Wet et al.’ 1987) which encodes a 61 kDa 
monomelic protein. Firefly luciferase does not require post-translational processing 
for enzymatic activity (de Wet et al.，1985; Wood et al., 1984). 
When an excess of ATP is injected into a solution containing the other 
reactants and purified enzyme under standard conditions, the reaction emits a flash of 
light which peaks 0.3 s later and decays over a period of several minutes (DeLuca et 
al., 1978). The intensity of the transient flash, the time required to obtain maximum 
emission, and the rate of luminescent decay, all depend on the reaction conditions 
and purity ofluciferin and luciferase preparations (DeLuca et al., 1978; Subramani et 
al., 1988). Light emission is measured most sensitively with a luminometer. Since 
mammalian cells do not possess an activity similar to that of luciferase, the 
sensitivity of this reporter gene system, in theory, is limited by the 'background 
noise' of the luminometer (Alam et al, 1990). The sensitivity of the assay permits 
the use of very small amounts of plasmid transfected into cells, which avoids the 
potentially anomalous effect of high concentrations of DNA (Selden et al., 1986). 
Thus, the activity of the reporter enzyme provides an indirect measurement of the 
transcriptional activity of the promoter sequence. 
The reporter gene used in studies of signal transduction are inactive or 
weakly active with respect to transcription until the transcriptional factor proteins 
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that bind to and active the promoter as a consequence of receptor-mediated signal 
transduction. The activated promoter drives the transcription of a reporter gene 
which is then quantified by the enzymatic activity of the protein product. 
Chimeric transcriptional factor reporter genes have been used to characterize 
receptor activation of the MAPK cascade. Eukaryotic transcriptional factors 
generally contain two domains: a regulatory domain containing a number of serine, 
threonine or tyrosine residues, which act as a substrate for phosphorylation by 
upstream kinases, which are activated through coupling to receptors. The DNA 
binding domain and transactivation domain is able to recognize and bind to specific 
transcriptional factor binding sites such as GAL4, resulting in the activation of any 
promoter containing that sequence. Thus, the chimeric proteins consist of the 
regulatory domain of one transcriptional factor fused to the DNA binding and 
transactivation domain of a second. In contrast to conventional MAPK assays, or 
immunoprecipitation and Western blotting to identify phosphorylated MAPK 
(Fukuda et al, 1997)，the reporter gene assay allows the rapid detection of the 
activation of MAPK enzymes in whole cells and allows the identification of the 
transcriptional factors that are regulated as a result of MAPK activity. 
The PathDetect® Elkl rra^zs-Reporting System (PathDetect system; 
Stratagene) consists of two plasmids (Fig. 3.2): trans-activator (pFA2-Elk) and the 
firefly reporter (pFR-Luc) plasmid. The trans-activator plasmid encodes a chimeric 
trans-activator protein, which is then constitutively expressed in the cells. The trans-
activator plasmid contains the DNA binding domain of the yeast GAL4 (residues 1-
147; GAL4-dbd), followed by the trans-activation domain of the transcriptional 
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factor Elk-1 (residues 307-427)，which act as a substrate for phosphorylation by 
upstream kinases such as ERKl/2. The firefly reporter plasmid contains the firefly 
luciferase reporter gene, which is driven by a promoter with 5 yeast GAL4 binding 
sites that respond to GAL4 fusion. Once the Elk-1 domain is phosphorylated by 
upstream kinases and activated, the transactivator protein subsequently activates the 
transcription of firefly luciferase gene through the binding of GAL4 response binding 
site located in the firefly reporter plasmid. Thus, the firefly luciferase activity reflects 
the ERKl/2 activation in the cells. 
Cells were also cotransfected with a second reporter vector, renilla {Renilla 
reniformis) luciferase plasmid (pRL-SV40) or (3-galactosidase (P-gal) plasmid 
(Section 3.3.1.2)，for an internal control reporter to measure the variability in DNA 
transfection efficiency. The mechanism of the PathDetect system is illustrated in 
Figure 3.3. A comparison between different reporter vectors to account for the 
transfection efficiency is shown in Chapter 4. 
A negative control plasmid (pFC2-dbd) (Fig. 3.2) encoding only the DNA 
binding domain of GAL4, which does not result in luciferase transcription, can be 
used to demonstrate that firefly luciferase expression is dependent on the 
phosphorylation of Elk-1 by upstream kinases. As a positive control, cells can be 
cotransfected with the trans-activator and a positive control plasmid (pFC-MEKl) 
(Fig. 3.2) which encodes the upstream kinase (MEKl) of the ERKl/2 pathway. 
These together demonstrate that activated MEK indeed result in firefly luciferase 
expression. 
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The resultant activity of the reporter enzyme (firefly luciferase) in each 
extract is normalised to the activity of the second reporter enzyme (renilla luciferase 
or p-gal) within that extract. The standardization of data to the activity of a second 
reporter enzyme controls for the interassay variabilities due to variations in 
transfection efficiency. The standardization of data to the total protein content of the 
extract controls for varations in cell numbers and the extract collection. 
3.3.1.2 p-galactosidase assay 
Transfection of cells with the p-galactosidase (p-gal) gene is used as a reporter 
system to estimate the transfection efficiency. The high sensitivity P-gal assay kit 
(Stratagene) was used, which determines the P-gal activity in the lysates of cells 
transfected p-gal reporter plasmid. The enzyme P-gal catalyzes the hydrolysis of p-
gal, including lactose and the galactoside analog chlorophenol red-p-D-
galactopyranoside (CPRG). The enzyme converts the yellow-orange CPRG into 
galactose and the chromophore chloroprene red, yielding a dark red solution. 
3.3.1.3 Transient transfection of cells 
Cells were transfected, in duplicate, according to section 3.2 with the PathDetect 
plasmids, pFR-Luc (0.5 ^ig/ml), pElk-1 (0.05 ^ig/ml) and pRL-SV40 (0.01 ^g/ml) or 
P-gal (0.5 i^g/ml); these being optimised concentrations as discussed in Chapter 4. 
For positive and negative control groups, cells were transfected with pFC-MEKl (50 
ng/ml) and pFC2-dbd (50 ng/ml), respectively. 
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3.3.1.4 Cell assay 
Following overnight incubation in serum-free medium, the non-selective 
cyclooxygenase (COX) inhibitor (3 |iM indomethacin), was added to the serum-free 
culture medium in order to prevent endogenous production of prostaglandins, and 
cells were then incubated with test drugs or HBS for 30 min, followed by addition of 
cicaprost or HBS for a further 5 h. When testing PMA, the drug was removed after 
30 min contact time. 
Cell lysates were prepared according to manufacturer's instructions. The 
medium was aspirated and cells were rinsed twice with 2 ml PBSA. Cells, not 
transfected with renilla or P-gal reporter gene, were lysed with 300 IX Cell Lysis 
Buffer (CLB, Promega). As cell lysates prepared using CLB would not yield optimal 
result when assaying for renilla and p-gal luciferase activity, cells transfecting with 
renilla or p-gal reporter plasmids were lysed with 500 Passive Lysis buffer 
(Promega). Cell lysates were centrifuged at 12,000 g for 15 sec. Supematants were 
transferred to microtubes and tested immediately for luciferase activity using the 
Turner Designs Model TD20/20 luminometer. Using P-gal as the reporter system, 
samples were tested for P-gal activity by using a microtiter plate reader. Protein 
content of cell lysates (10 |il) was determined using Micro BCA protein assay 
(Pierce) with bovine serum albumin as standard. Cell lysates were stored for up to 1 
week for the p-galactosidase and protein assay. 
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3.3.1.5 Luciferase assay 
The assays for firefly and renilla luciferase activity were performed sequentially on 
the same sample, using one reaction tube with the Dual luciferase assay kit 
(Promega). Samples of the cell lysate (20 ^il) were put into a microtube and mixed by 
pipeting with 100 Luciferase Assay Reagent II to determine the firefly luciferase 
activity (Flue) using a luminometer. To determine the renilla luciferase activity 
(Rluc), Stop & Glo Reagent (100 |il) was then added. The sample was vortexed 
briefly, then replaced in the luminometer. The luminometer was programmed to 
perform a 2 second premeasurement delay, followed by a 10 sec measurement period 
for both firefly and renilla luciferase assay. 
For the experiment using P-gal as reporter gene, the Luciferase assay kit 
(Promega) was used. Samples of the cell lysate (20 }il) were put into a microtube and 
mixed by pipeting with 100 i^l Luciferase Assay Reagent to determine the firefly 
luciferase activity with luminometer programmed as above. All the luciferase assays 
were performed immediately after lysis of cells. Firefly and renilla luciferase activity 
are expressed in relative light units (RLU). 
3.3.1.6 Micro p-gal assay 
Samples of cell lysate (20 |il) were put into a 96-well plate, followed by 130 of 1 x 
CPRG substrate, and incubated at 37�C for 30 min. The reaction was stopped by 
addition of 80 i^l stop solution, and optical density was measured at 570 nm. Results 
‘ “Page 74 
Chapter 3 Methods 
are expressed as chorophenol red formed per min incubation time (nmol/min) or 
activity of P-galactosidase (U). 
3.3.1.7 Data analysis 
Firefly luciferase activity (Flue) reflecting the Elk-1 activation was corrected for the 
transfection efficiency using renilla luciferase activity (Rluc) or P-gal activity (U) as 
shown above, and for the amount of protein in cell lysates (mg). Using the renilla 
luciferase as the reporter system, the firefly luciferase activity is expressed as 
normalised luciferase activity [(Fluc/Rluc)/ mg of cellular protein]. Using p-
galactosidase as the reporter system, the firefly luciferase activity is expressed as 
specific luciferase activity [(Fluc/U)/ mg of cellular protein]. For cicaprost log 
concentration-response curves, normalised luciferase activity was presented against 
the maximum response to cicaprost obtained within the same experiment. Statistical 
levels of significance (p<0.05) were calculated using one-way analysis variance with 
Dunnett's post-test. 
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antibiotic 
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Figure 3.1 Illustration of the typical reporter vector. Ori represents the prokaryotic 
orgin of replication. The arrow indicates the direction of transcription of the reporter 
gene (Alam et ai, 1990). 
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trans-activator plasmid (pFA2-Elkl) 
——promoter | GAL4-dbd (1-147) | Elk-1 (307-427) 
reporter plasmid (pFR-Luc) 
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binding element — reporter gene 
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promoter MEKl  
Figure 3.2 Different components in the PathDetect® Elkl rran^-Reporting System 
(Stratagene). 
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Figure 3.3 The mechanism of PathDetect® Elkl Trans-RQportmg System 
(Stratagene). For details, see section 3.3.1. 
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3.3.2 Western Blotting 
3.3.2.1 Introduction 
In Western blotting experiments, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was used to resolve separate components of a protein 
mixture according to the molecular weights of proteins. The electophoresed proteins 
are transferred to nitrocellulose membranes and analysed using various probes such 
as antibodies. The protein of interested can then be visualized by autoradiographic 
detection on X-ray film. 
3.3.2.2 Transient transfection of cells 
For those experiments using CHO cells, cells were transfected in 6-well plates 
according to section 3.2. For those experiments using NG108-15 and SK-N-SH cells, 
which endogenously express IP-receptors, cells were assayed in 6-well plates after 
serum starvation overnight without transfection. 
3.3.2.3 Cell assay 
Following overnight incubation in serum-free medium, indomethacin (3 |aM) was 
added to the serum-free medium and cells were then incubated with test drugs or 
medium for 30 min, followed by addition of cicaprost or medium for a specific time 
period. For the cells which were tested with drugs dissolved in DMSO, a 1% DMSO 
solution was added as control, followed by addition of cicaprost or medium for a 
specific time period. To stop the reaction, the medium was aspirated and cells were 
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rinsed twice with 2 ml PBSA. Cells were lysed with lysis buffer (50 mM Tris-base, 
100 mM NaCl, 5 mM EDTA, 67 mM NaAPzOy, 0.01% Triton X-100, 0.2 mM PMSF, 
0.2 mM NasCUV，1 mM DTT, 4 |aM leupeptin, 4 ng/ml aprotinin). For experiments 
using CHO cells, 250 |LI1 of lysis buffer was used while 200 |il of lysis buffer was 
required for NG108-15 and SK-N-SH cells. The cell lysates were centrifuged at 
15,000 X g for 15 min at room temperature, and protein content of supematants (10 
III) were determined using Micro BCA protein assay (Pierce) with bovine serum 
albumin as standard. For detecting the activated ERKl/2 activity, cell samples can be 
stored up to 1 week, while the sample can be stored up to 1 month for detecting total 
endogenous ERKl/2. 
3.3.2.4 Protein electrophoresis and transfer 
Cell lysates and molecular weight markers (New England Biolabs) were denatured at 
100�C for 5 min with 6X sample buffer. Molecular weight marker (5 \x\) and equal 
amounts of cell lysates (20-30 protein/lane) were separated on 12% 
polyacrylamide SDS gel and electrophoretically transferred overnight to Hybond 
nitrocellulose membrane (Amersham) at 4°C. Localization of proteins on the 
membrane was detected by Ponceau S staining and the size of proteins was estimated 
by comparison with the molecular weight marker. 
3.3.2.5 Immunodetection 
The membranes were destained with TEST and incubated with antibodies (Cell 
Signaling; 1:1000) which detect the phosphorylated ERKl/2 (pERKl/2) and the total 
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level of endogenous ERKl/2 (ERKl/2) for 2 h on ice. The membranes were then 
incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibody 
(New England Biolabs; 1:2000) and visualised by chemiluminescence with ECL 
detection reagents (Amersham) and exposed to X-ray film for 10 min. The pERKl/2 
antibody specifically detects the activated dually phosphorylated form of ERKl/2 in 
the cells. The ERKl/2 antibody is used to detect the total endogenous activity of 
ERKl/2 inside the cell. The procedures involved in the Western blotting experiment 
are shown in Figure 3.4. The band density, which indicates the activated form of 
ERKl/2, was then quantified by the FluorChem imager (Alpha Innotech) and 
expressed as Integrated Density Value (IDV). Without a saturated density, bands 
within a linear range of the IDV measurement generally give a quantitative 
information. To confirm the response of different treatments on ERKl/2 activation, 
the more reliable and readily quantifiable PathDetect system is recommended. 
‘ “ P a g e 81 
Chapter 3 Methods 
molecular sample 1 sample 2 sample 3 
weight marker 
1 I — I I — I I I r 
83k Da  62k Da  
47k Da  
pERKl (44 k D a ) ~ • I Z Z I ^ Z Z Z Z H 
pERK2 (42 k D a ) • 
32k Da  25k Da  
6.5k Da slab of SDS gel 
/ SDS gel HRMnked 
I , 1/ ^ WM secondary antibody 
/nitrocellulose ^ O primary antibody 
/ membrane / / I I I I ] . , / ^ side view 
• front view 
pERKl • 
pERK2 — • 
detection with X-ray film 
Figure 3.4 A summary of western blotting experiment. 
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3.4 MEASUREMENT OF ADENYLYL CYCLASE ACTIVITY 
3.4.1 [^H]-adenine prelabelling method 
The activity of adenylyl cyclase, which catalyses the formation of cyclic AMP from 
ATP, can be measured by labelling cells with [^H]-adenine and measuring the 
conversion of [^H]-ATP to [^H]-cyclic AMP. The phosphodiesterase inhibitor iso-
butyl-methyl-xanthine (IBMX) at 1 mM was added to the assay buffer to prevent the 
breakdown of [^H]-cyclic AMP, and indomethacin (3 |iM) was added to prevent 
endogenous production of prostaglandins. 
3.4.1.1 Preparation of columns 
Dowex columns (AG50W-X4) were prepared by mixing 50 g of dowex resin with 
100 ml HCL (1 M) and placing evenly in 50 chromatography columns (Bio-Rad). 
The columns were washed with 4 ml HCL (1 M), followed by 10 ml ultra-pure water 
before the experiment. Alumina columns were prepared by adding 0.6 g of neutral 
alumina to each of 50 columns, followed by 8 ml imidazole buffer (0.1 M，pH 7.5). 
Dowex columns were rinsed with 4 ml HCl (1 M), followed by 10 ml ultra-pure 
water while alumina columns were rinsed with 8 ml imidazole buffer (0.1 M, pH 7.5) 
three times respectively prior to use. 
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3.4.1.2 Incubation of cells 
Cells were harvested from the petri dish using trypsin/EDTA treatment three days 
before transfection. Cells (1 x lO"^  cells/well) were then seeded to each well of a 24-
well plate containing 1 ml culture medium. After reaching approximately 80% 
confluency, cells were transfected as described in previously. One day after 
transfection, cells were cultured in 0.5 ml medium with 1% FBS plus penicillin (100 
units/ml) and streptomycin (100 |ig/ml). In the late afternoon, 5 of [^H]-adenine, at 
a final concentration of 1 }iCi/ml, was added to each well. 
Following overnight (18 — 20 h) incubation with [^H]-adenine, the medium 
was aspirated and each well was washed twice with 1 ml HBS buffer to remove 
unincorporated [^H]-adenine. HBS (1 ml) containing 1 mM EBMX and 3 i^M 
indomethacin was added to each well. Test compounds (10 nl) were added to each 
well and the 24-well plates were placed in a water bath (37�C) for 30 min. To stop 
the reaction, plates were transferred onto ice, buffer was aspirated, and 1 ml ice-cold 
50/0 trichloroacetic acid containing 1 mM ATP was added to lyse the cells. The plates 
were left on ice for at least 30 min before loading the cell lysates onto Dowex 
columns. 
3.4.1.3 Measurement of I^H]-cyclic AMP production 
[^H]-cyclic AMP was separated from total [^H]-adenine nucleotides (AXP) by 
column chromatography using dowex and alumina columns (Barber et al, 1980). 
The lysates were transferred onto dowex columns followed by 3 ml ultra-pure water. 
The eluant was collected into 20 ml scintillation vials and mixed with 10 ml 
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scintillant (Optiphase Hi-safe 3). The eluants were then counted in a liquid 
scintilllant counter (Packard LS2900TR) to determine the total [^H]-AXP activity. 
The dowex columns were then washed with 10 ml ultra-pure water on the top of 
alumina columns. When the eluants were completely removed from both sets of 
columns, the [^H]-cyclic AMP was collected by adding 6 ml imidazole buffer (0.1 M, 
pH 7.5) to alumina columns. The eluants were mixed with 10 ml scintillant and 
counted in a liquid scintillation counter. Blank samples without cell lysates were run 
through the columns in parallel in order to determine the background signal for the 
column (typically 1 0 0 - 150 dpm) and these values were then subtracted from all the 
test values. 
3.4.1.4 Data analysis 
Cyclic AMP production is expressed as %conversion ([^H]-cyclic AMP/total 阳-
adenine) x 100%. Each experiment was performed in duplicate. 
3.5 MEASUREMENT OF PHOSPHOLIPASE C ACTIVITY 
3.5.1 myo-[3H]-inositol labelling method 
The activity of PLC was measured by determine the accumulation of [^H]-inositol 
phosphates compared to total [^H]-inositol phospholipids (Berridge et al., 1984). 
Lithium chloride (20 mM) was included in the assay buffer to prevent the recycling 
of inositol phosphate back into inositol phospholipids (Berridge, 1984)，and the non-
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selective cyclooxygenase (COX) inhibitor, indomethacin (3 \M). was added to 
prevent endogenous production of prostaglandins. 
3.5.1.1 Preparation of columns 
Dowex resin (AG 1-X8, Bio-Rad) was washed twice with an equal volume of ultra-
pure water. Resin suspension (2 ml) was transferred to each polyprep column (Bio-
Rad). The columns were washed with 5 ml 2 M ammonium formate/0.1 M formic 
acid, prior to use. 
3.5.1.2 Incubation of cells 
Cells were harvested from the petri dish using trypsin/EDTA treatment three days 
before transfection. Cells (1 x lO* cells/well) were then seeded to each well of a 12-
well plate containing 1 ml culture medium. After reaching approximately 80% 
confluency, cells were transfected as described in previously. One day after 
transfection, cells were cultured in 1 ml medium with 1% FBS plus penicillin (100 
units/ml) and streptomycin (100 |ig/ml). In the late afternoon, 10 i^l of myo-[^H]-
inositol, at a final concentration of 2 |iCi/ml, was added to each well. 
Following 40 h incubation with myo-[^H]-inositol, the medium was aspirated 
and each well was washed twice with 1 ml HBS buffer to remove unincorporated 
[^H]-inositol. HBS (1 ml) containing 20 mM lithium chloride and 3 |iM 
indomethacin was added to each well. Test compounds (10 \x\) were added to each 
well and the 12-well plates were placed in a water bath (37�C) for 60 min. To stop 
the reaction, plates were transferred onto ice, buffer was aspirated, and 0.75 ml ice-
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cold formic acid was added to lyse the cells. The plates were left on ice for at least 60 
min before loading the cell lysates onto Dowex columns. 
3,5,1,3 Measurement of [^HJ-inositol phosphate production 
[^H]-inositol phosphate was separated from total [^H]-inositol phosphlipids by 
column chromatography using dowex columns (Berridge et al., 1984). The columns 
were washed with 5 ml 2 M ammonium formate/0.1 M formic acid, 2 ml ultra-pure 
water and 2 ml of 0.05% ammonia solution prior to the experiment. The lysates were 
transferred onto dowex columns followed by 3 ml of ammonia solution. The eluant 
was collected into 20 ml scintillation vials and mixed with 7.5 ml scintillant 
(Optiphase Hi-safe 3). The eluants were then counted in a liquid scintilllant counter 
(Packard LS2900TR) to determine the [^H]-inositol phosphlipids. The dowex 
columns were then washed with 4ml of 40 mM ammonium formate/O.l formic acid 
over the waste container. The [^H]-inositol phosphates were eluted with 5ml of 2 M 
ammonium formate/O.l M formic acid and mixed with 10 ml scintillant and counted 
in a liquid scintillation counter. Blank samples without cell lysates were run through 
the columns in parallel in order to determine the background signal for the column 
(typically 100 - 150 dpm) and these values were then subtracted from all the test 
values. 
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3.5.1.4 Data analysis 
Inositol phosphte production is expressed as %conversion ([^H]-inositol 
phosphates/total [^H]-inositol phosphlipids) x 100%. Each experiment was 
performed in duplicate. 
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Chapter 4 
Results 
4.1 VALIDATION OF PATHDETECT® ELK1 TR^AA/S-REPORTING SYSTEM 
4.1.1 Introduction 
The PathDetect® Elkl Trans-Reporting System (PathDetect system) (Stratagene) 
consists of two plasmids: the firefly reporter plasmid (pFR-Luc) and the trans-
activator plasmid (pFA2-Elk). In cells transfected with the two PathDetect reagents, 
increased luciferase activity reflects activation of Elk-1. Once the Elk-1 domain in 
trans-activator protein is activated and phosphorylated by upstream kinases, it drives 
the activation of the firefly luciferase gene expression (Fig. 3.3). The two plasmids 
were co-transfected into CHO cells and cells were assayed as described in Chapter 3. 
Firefly luciferase activity was then measured using a luciferase assay kit (Promega) 
according to the manufacturer's instructions, as described in Chapter 3. 
4.1.2 Internal control 
In order to validate the PathDetect system, two groups of CHO cells were transfected 
with a negative control and positive control plasmid respectively, as well as the 
firefly reporter plasmid. A control group of CHO cells were transfected with the 
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firefly reporter and activator plasmid only; thus only basal activated Elk-1 activity 
was detected. In the negative control group, the firefly reporter plasmid and a 
negative control plasmid (pFC-dbd) encoding the yeast GAL4 binding domain only 
were used. No mammalian transcriptional factors can efficiently bind to pFC-dbd. 
Therefore transfected cells cannot be activated by other upstream kinases such as 
ERKl/2. In addition, firefly luciferase is not endogenously expressed in mammalian 
cells. It is expected that a negative control group should give a low background 
firefly luciferase expression. Therefore, a negative control group is able to 
demonstrate that the firefly luciferase expression is dependent on the 
phosphorylation of Elk-1 transcriptional factor in the cells. In a positive control 
group, the firefly reporter, trans-activator and positive control plasmid (pFC-MEKl) 
encoding MEKl protein was co-transfected into CHO cells. MEKl is a well-known 
upstream activator of transcriptional factor Elk-1. Therefore, a positive control group 
is able to demonstrate that MEKl can activate Elk-1 transcriptional factor and reflect 
the response in firefly luciferase expression. 
In Figure 4.1，the control group of cells showed that pFA2-Elk-transfected 
CHO cells gave 36.85 土 2.04 RLU x 10\ n = 2 of firefly luciferase activity. The 
negative control group showed 0.40 ±0.14 RLU x 1 0 \ n = 2, which means there is 
low background level of endogenouse ERKl/2 activity in CHO cells. The lower 
response of firefly luciferase activity in the negative control group means the firefly 
luciferase is only expressed with the activation of the Elk-1 transcriptional factor. In 
contrast, when CHO cells were transfected with a positive control plasmid encoding 
MEKl, the positive control group showed 518 土 126 RLU x n = 2, giving a 
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14.00 士 1.88 fold, increase in luciferase activity compared to the control group. A 
high expression of firefly luciferase activity indicated that firefly luciferase gene 
expression required activation of the Elk-1. 
4.1.3 Response to cicaprost and ATP 
In order to study the ERKl/2 activity of mlP-receptor in CHO cells, mlP-receptor 
cDNA (0.5 ng/ml) was transfected into CHO cells (mlP-CHO) and the receptors 
were activated by 10 ^M cicaprost. Firefly luciferase activity was assayed as 
described in Chapter 3. Cicaprost stimulated ERKl/2 activity in mlP-CHO cells by 
1.45 士 0.05 fold basal, n = 2. The basal firefly luciferase activity was 0.34 土 0.40 
RLUx 1 0 \ n = 2. 
In order to see a non-transfected receptor also function in CHO cells, the P2 
purinergic (P2Y) receptors, which are endogenously expressed in CHO cells, were 
tested. P2Y receptors have been shown to activate ERKl/2 by coupling to a Gq-
mediated pathway (Dickenson et al., 1998; Neary et al, 1999). ATP activates Gq-
coupled P2Y receptors in CHO cells to stimulate inositol phosphate production 
(Murray-Whelan et al., 1995). ATP (100 ^M) which activates [^H]-inositol 
phosphate accumulation similar to that of cicaprost (10 \iM) (Chow et aL, 2001) was 
used as a positive internal control to validate the transfection of mlP in the 
PathDetect system. 
ATP (100 |iM) increased ERKl/2 activity in CHO cells to 1.55 土 0.10 fold 
basal; with the basal firefly luciferase activity was 36.85 土 2.04 RLU, n = 2. These 
“ Page 91 
Chapter 4 Results 
results suggested that both transiently transfected and endogenously expressed 
receptors couple to Gq can stimulate ERKl/2 activity in CHO cells 
4.1.4 Normalisation of ERK1/2 activity with transfection efficiency 
In order to estimate the efficiency of transfection of the plasmid cDNA into the cells, 
two reporter plasmids were introduced into different groups of cells: the renilla 
luciferase reporter plasmid and the p-gal reporter plasmid. CHO cells were 
transfected with the PathDetect System as well as the renilla luciferase reporter 
plasmid (0.02 |ag/ml) or P-gal plasmid (0.5 j^g/ml) as mentioned in Chapter 3. Cell 
lysates were then analysed using the Dual-Luciferase assay kit (Promega) or P-gal 
assay kit (Stratagene), respectively. All the results were then normalised using the 
protein content of each sample to account for any variation in cell number. 
The cicaprost-stimulated ERKl/2 activity was expressed as "normalised 
luciferase activity" for the Dual luciferase assay and "specific luciferase activity" for 
the P-gal assay, as described in Chapter 3. Cicaprost showed a 1.93-fold and 1.58-
fold increase in ERKl/2 activity in the Dual luciferase assay and the P-gal assay, 
respectively (Fig. 4.2). However, when comparing the protein concentration in the 
two assays, a high amount of cDNA transfected into the cells lowered protein 
concentration by half (Fig. 4.3). The total amount of cDNA in mlP-CHO cells for the 
Dual luciferase assay and the p-gal assay was 1.57 |ig/ml and 2.05 |^g/ml, 
respectively. Therefore, the renilla luciferase reporter plasmid was chosen to measure 
the transfection efficiency in mlP-CHO cells, in order to optimise the cDNA 
concentration and reduce the toxicity of the transfection reagents to the cells. Also, 
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the assay methodology for renilla luciferase is much easier than that of p-gal as the 
same sample can be used for measuring firefly luciferase activity in the same 
microtube. In order to further minimise the amount of the cDNA needed for 
transfection, different concentrations of firefly luciferase reporter plasmid were 
tested; 0.5 \xg/m\ was found to be the minimum amount of the plasmid needed in the 
assay (data not shown). Therefore, the total amount of cDNA transfected into CHO 
cells was reduced to 1.06 |ig/ml for subsequent experiments. 
4.1.5 Cicaprost response in CHO cells in the absence of mlP-receptor 
To confirm that cicaprost-stimulated ERKl/2 activity in CHO cells required the 
presence of mlP-receptors, CHO cells were transfected with the same amount of 
vector DNA (pcDNAl.l-CHO). As shown in Figure 4.4, the mlP-CHO cells showed 
a 9.36-fold increase in ERKl/2 activity in response to cicaprost (10 \xM). However, 
the pcDNAl.l transfected CHO cells failed to respond to cicaprost indicating that 
cicaprost must be stimulating ERKl/2 activity through IP-receptors. Interestingly, a 
high level of the basal normalised luciferase activity was found in pcDNAl.l-CHO 
cells when compared to the mlP-CHO cells. In the process of the study, I observed a 
similar effect in a later experiment in hIP-CHO cells (see Chapter 4.4). 
4.1.6 Normalised luciferase activity reflecting ERK1/2 activation 
In order to dissect the ERKl/2 cascade and confirm that the activation of firefly 
luciferase activity reflects the direct phosphorylation of Elk-1 transcriptional factor 
via the ERKl/2 cascade, two MEK inhibitors (U0126 and PD098059) were tested. 
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Both U0126 and PD098059 block ERKl/2 activation, but through different 
mechanisms. U0126 was identified as an inhibitor of MEKl and MEK2 by direct 
inhibition with IC50 values of 0.07 ^iM and 0.06 respectively (Duncia et al, 
1998). U0126 is a potent and specific inhibitor of dual specificity kinase MEKl and 
MEK2 both in in vitro enzymatic assay as well as intracellularly where U0126 blocks 
phosphorylation and activation of ERKl/2 (Favata et al.’ 1998). U0126 is selective 
for MEKl and 2 and showed little effect on the kinase activities of PKC, Raf, MEKK, 
ERK, JNK, MKK3, MKK4, MKK6, Cdk2 or Cdk4 (Favata et al,, 1998). The other 
MEK inhibitor, PD098059, was also identified in an in vitro screen for inhibitors of 
ERKl/2 activation (Alessi et al., 1995; Dudley et al, 1995). PD098059 has been 
shown to inhibit the dephosphorylated form of MEKl. However, it has been reported 
that PD098059 does not inhibit the phosphorylated form of MEKl, but instead 
prevents the activation and phosphorylation of MEKl in vitro and in vivo. It has been 
reported that PD098059 works by inhibiting phosphorylation of MEKl by upstream 
activators at 50 \iU (Alessi et al, 1995) with IC50 value of approximately 10 ^iM 
(Favata et al, 1998). 
In the presence of cicaprost at its EC50 concentration (100 nM; obtained in the 
concentration-response curve in Section 4.2)，I tested the two MEK inhibitors 
(U0126 and PD098059) at 10 \xM to see if they blocked MEK phosphorylation and 
thus activation of ERKl/2. Neither MEK inhibitor showed any statistically 
significant effect on basal normalised luciferase activity, indicating that there is no 
effect on basal ERKl/2 activity (data not shown). However, U0126 completely 
inhibited cicaprost-stimulated normalised luciferase activity in mlP-CHO cells while 
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PD098059 inhibited cicaprost-stimulated activity to 42 士 22o/o of control cicaprost 
response, n = 3 (Fig. 4.5). The low solubility of PD098059 in aqueous solution 
precludes testing PD098059 at higher concentrations. These results suggested that 
cicaprost-stimulated Elk-1 activation is mediated by MEK in ERK cascade but not 
through JNK cascade. 
4.1.7 Conclusion 
In the PathDetect System, firefly luciferase gene expression is used to quantify the 
activity of the transcriptional factor Elk-1. The effect of the two MEK inhibitors 
indicated that activation of Elk-1 via the ERKl/2 cascade, rather than the JNK 
cascade. Using low amounts of renilla luciferase gene encoding plasmid, the ERKl/2 
activity could be normalised to account for any differences in the transfection 
efficiency between different treatment groups of CHO cells. Protein concentrations 
of different treatment groups of cells also indicated the toxicity of the high cDNA 
concentration and the transfection reagents to the cell system. With the use of renilla 
luciferase gene expression and protein concentration of the cells, I optimised the total 
cDNA concentration of this transient transfection model to 1.06 |ig/ml i.e. 0.5 jag/ml 
mlP, 0.5 |ig/ml firefly luciferase reporter plasmid, 0.05 jig/ml activator plasmid and 
0.01 \xg/m\ renilla luciferase reporter plasmid. 
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Figure 4.1 Firefly luciferase expression in CHO cells transfected with different 
components in the PathDetect System. Firefly luciferase activity was determined as 
described in Chapter 3. Results represent as mean 土 S.D. of two experiments, each 
performed in triplicate. All the cells were transfected with firefly luciferase reporter 
plasmid (1.0 |ig/ml). The control group of CHO cells were transfected with 50 ng/ml 
trans-activator plasmid (pFA2-Elk) to show basal Elk-1 activation. The negative 
control group was transfected with 50 ng/ml negative control plasmid (pFA-dbd) 
alone, to show that the expression of firefly luciferase is dependent on the 
phosphorylation of Elk-1. The positive control group was transfected with 50 ng/ml 
pFA2-Elk and positive control plasmid (pFA-MEKl) to show that expression of 
firefly luciferase activity required upstream kinase activation. 
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(A) ERK1/2 activity in mlP-CHO cells (Dual luciferase assay) 
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Figure 4.2 (A) Effect of cicaprost on normalised luciferase activity in mlP-CHO cells 
transfected with firefly luciferase reporter plasmid (1.0 \ig/m\), trans-activator 
plasmid (0.05 |ag/ml) and renilla luciferase reporter plasmid (0.02 |ig/ml). (B) Effect 
of cicaprost on specific luciferase activity in mlP-CHO cells transfected with firefly 
luciferase reporter plasmid (1.0 |ag/ml), trans-activator plasmid (0.05 }ig/ml) and P-
gal reporter plasmid (0.5 |ig/ml). Firefly luciferase, renilla luciferase and (3-
galactosidase activity was determined and expressed as described in Chapter 3. 
Triplicate results from one experiment. 
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Figure 4.3 Protein concentrations of mlP-CHO cells transfected with PathDetect 
reagents as well as renilla luciferase reporter plasmid (0.02 |ig/ml) or P-gal reporter 
plasmid (0.5 |ig/ml). Protein concentration was determined as described in Chapter 
3. Triplicate results from one experiment. 
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Figure 4.4 Effect of cicaprost on ERKl/2 activity in pcDNAl.l-CHO cells and mlP-
CHO cells. Cells were transfected with firefly luciferase reporter plasmid (0.5 
fig/ml)，renilla luciferase reporter plasmid (0.02 jig/ml), trans-activator plasmid (0.05 
^g/ml) and mlP-receptor cDNA (0.5 ^ig/ml) or pcDNAl.l (0.5 |ag/ml). Normalised 
luciferase activity was determined as described in Chapter 3. Triplicate results from 
one experiment. 
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Figure 4.5 Effect of MEK inhibitors on cicaprost-stimulated ERKl/2 activity using 
the PathDetect system. mlP-CHO cells were preincubated with U0126 or PD098059 
for 30 min and tested with cicaprost (100 nM) for a further 5 h. Control basal and 
cicaprost-stimulated normalised luciferase activity is 0.42 ±0.11 and 0.83 ± 0.1, n = 
3，respectively. Results represent mean 土 S.E.M. of three experiments, performed in 
duplicate. (*p<0.05; **p<0.01) 
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4.2 CHARACTERIZATION OF IP-RECEPTORS 
4.2.1 IP-receptor activation of adenylyl cyclase and phospholipase C 
The findings in various systems suggest that prostacyclin stimulates adenylyl cyclase 
and produces cyclic AMP in a Gs-mediated pathway (Halushka et al” 1989). By 
expressing the cloned IP-receptors, the multiple coupling capacities of IP-receptors 
in transfection systems have been demonstrated. These expression studies showed 
that activation of cloned human and mouse IP-receptors with iloprost results in 
coupling to Gs and activation of adenylyl cyclase (Boie et al., 1994; Namba et al., 
1994). In addition to the cyclic AMP response, iloprost can also stimulate 
phospholipase C leading to increases in inositol phosphates and intracellular calcium 
by a pertussis toxin-insensitive Gq-mediated pathway in cells expressing human or 
mouse IP-receptors (Boie et al., 1994; Namba et aL, 1994; Smyth et al., 1996). 
In studies performed in our laboratory, we have shown that in CHO cells 
transiently expressing the mlP-receptor, cicaprost activated both adenylyl cyclase 
and phospholipase C in a concentration-dependent manner producing a 7.72-fold 
stimulation of adenylyl cyclase activity, and a 3.66-fold stimulation of phospholipase 
C activity (Fig 4.6) (Chow et al., 2001). 
Neuroblastoma cells, which endogenously express CP-receptors, have also 
been used to study IP-receptor coupling to different G proteins. The human 
neuroblastoma (SK-N-SH) cell line and the rat/mouse neuroblastoma/glioma cell line 
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(NG108-15) were introduced in this study. [^H]-cyclic AMP and [^H]-inositol 
phosphate data in Figure 4.6 and 4.7 were kindly provided by Helen Wise 
(Pharmacology Dept., CUHK) for comparison with my studies on ERKl/2. Cicaprost 
produced a log concentration-dependent increase in [^H]-cyclic AMP accumulation, 
with pECso values of 8.47 土 0.14 (n 二 3)，8.55 士 0.14 (n = 3)，and 7.48 土 0.03 (n = 4) 
for mEP-CHO, NG108-15, and SK-N-SH cells, respectively (Figs. 4.6 and 4.7). 
These results indicate that IP-receptors endogenously expressed or in transient 
transfection systems show a high capacity to couple to Gs proteins. The potency of 
cicaprost for stimulating the mouse/rat forms of the IP-receptor is significantly 
greater than that of the human receptor present in SK-N-SH cells. 
> 
Cicaprost also produced a log concentration-dependent increase in [^H]-
inositol phosphate accumulation only in mlP-CHO and NG108-15 cells; pECso 
values were 6.88 土 0.04 (n = 3) and 6.34 ± 0.13 (n = 3)，respectively (Figs. 4.6 and 
4.7). 
In summary, IP-receptors couple to Gs- and Gq-mediated pathways in mlP-
CHO and NG108-15 cells, with a higher sensitivity response to adenylyl cyclase. 
However, in theSK-N-SH cells, hlP-receptors can only activate adenylyl cyclase. 
4.2.2 IP-receptor activation of ERK1/2 in mlP-CHO cells 
4.2.2.1 PathDetect System 
To study the ERKl/2 regulation by IP-receptors, mEP-CHO cells were examined 
with the optimised conditions of the PathDetect system as discussed previously. 
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Cicaprost produced a concentration-dependent increase in ERKl/2 activity in mlP-
CHO cells, with around maximal 6-fold increase and a pECso value of 7.47 土 0.16，n 
= 3 (Fig. 4.6). When comparing the pECso value of [^H]-cyclic AMP (8.16) and [^H]-
inositol phosphate accumulation (6.85) from data in Figure 4.6, a downstream kinase 
activity should be amplified by the activity of second messengers, which should 
show a lower pECso value. Thus, activation of ERKl/2 in mlP-CHO cells likely 
occurs through a Gq-mediated pathway. In addition, Gq-coupled P2Y receptors 
endogenously expressed in wild type CHO cells could stimulate ERKl/2 activation. 
Taken together, I suspected that activation of ERKl/2 in mlP-CHO cells occurs 
through a Gq-mediated pathway rather than a Gs-mediated pathway. 
4.2.2.2 Western Blotting 
The regulation of ERKl/2 by IP-receptors was also examined using Western blot 
technique with mlP-CHO cells and stimulated with cicaprost (10 ^M). Following by 
cell lysis at specified times, antibodies detecting the phosphorylated form of ERKl/2 
(pERKl/2) activity and total level of endogenous ERKl/2 (ERKl/2) were then used 
to determine the ERKl/2 activation, as described in Chapter 3. 
Cicaprost produced a time-dependent activation of ERKl/2 in mlP-CHO cells, 
with no change in the total level of endogenous ERKl/2, giving a peak activation of 
ERKl/2 activity occurring at 10 min (Fig. 4.8). A 10 min incubation with PKC 
activator (10 |iM PMA) was used as a positive control, since PMA can activate 
ERKl/2 in a Raf-dependent manner (Kolch et ai, 1993). In the presence of cicaprost 
at its ECso concentration (100 nM) obtained in the concentration-response curve in 
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previous section, the more selective MEK inhibitor (10 |iM U0126) was tested to see 
whether it could block MEK phosphorylation and thus ERKl/2 activation. In Figure 
4.9，we see the inhibitory effect of 30 min pre-treatment with U0126 on cicaprost-
stimulated ERKl/2 activity. In addition, 10 [iM U0126 completely inhibited PMA-
stimulated ERKl/2 activation (Fig. 4.10). Results indicate that activation of ERKl/2 
in mlP-CHO cells occurs in a MEK-dependent manner. 
4.2.2.3 Conclusion 
In conclusion, using both the PathDetect system and Western blot method showed 
stimulation of IP-receptors with cicaprost resulted in activation of the ERKl/2 
) 
cascade in a concentration- and time-dependent manner. U0126 (10 |iM) is sufficient 
to inhibit the ERKl/2 activation through a MEK-dependent manner. By comparing 
the pECso values of [^H]-cyclic AMP and inositol phosphate accumulation with 
ERKl/2 activation by IP-receptor stimulation, I suspect that activation of ERKl/2 in 
mlP-CHO cells occurs through a Gq-mediated pathway rather than a Gs-mediated 
pathway. 
« 
4.2.3 Role of the Gs-mediated pathway in cicaprost-stimulated ERK1/2 
activation 
In the previous section, cicaprost was demonstrated to activate ERKl/2 in mlP-CHO 
cells. Cicaprost can stimulate both adenylyl cyclase and phospholipase C pathways 
in mlP-CHO cells (Kam et al., 2001). In all cells except the piglet cerebrovascular 
smooth muscle cells, the IP-receptor shows a higher affinity for the coupling to Gs 
“ “ “ “ Page 104 
Chapter 4 Results 
compared to Gq proteins. To determine whether the cicaprost-stimulated ERKl/2 
activation in mlP-CHO cells was mediated through coupling of the IP-receptor to Gs 
or Gq, mEP-CHO cells were pretreated with various enzyme activators or protein 
kinase inhibitors to identify the signaling pathway. 
4.2.3.1 Role of cyclic AMP 
, In order to study the role of cyclic AMP in cicaprost-stimulated ERKl/2 activation, a 
direct activator of adenylyl cyclase, forskolin, was introduced to mimic the effect of 
adenylyl cyclase. Cyclic AMP is hydrolysed within the cells by phosphodiesterases, 
therefore to prevent the hydrolysis of cyclic AMP, the non-selective > 
phosphodiesterase inhibitor 2-isobutyl-1 -methylzanthine (IBMX) was used. 
The PathDetect system showed that cicaprost (100 nM) produced a 4.08 土 
0.42 fold increase in ERKl/2 activity (n = 4). Direct activation of adenylyl cyclase 
with 10 |iM forskolin or preventing breakdown of cyclic AMP with 1 mM IBMX 
alone showed no significant effect on basal ERKl/2 activity (Fig. 4.11 (A)). 
However, preincubation of cells with forskolin or IBMX for 30 min significantly 
inhibited the cicaprost-stimulated ERKl/2 activity in mlP-CHO cells to 50.45 土 9.25 
and 6.49 土 5.22o/o of control cicaprost response, respectively (Fig. 4.11 (B)). Results 
showed that maintaining the catalytic action of adenylyl cyclase or preventing 
hydrolysis of cyclic AMP can inhibit cicaprost-stimulated ERKl/2 activity. 
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4.2.3.2 Role of protein kinase A 
PKA is activated by cyclic AMP. In respect to the inhibitory effect of cyclic AMP on 
cicaprost-stimulated ERKl/2 activation in mlP-CHO cells, I expected that PKA 
shows an inhibitory effect on cicaprost-stimulated ERKl/2 activation in mlP-CHO 
cells. Two PKA inhibitors, H-89 and Rp-cAMPS, were tested for effects alone and 
on cicaprost-stimulated ERKl/2 activity in mlP-CHO cells. The mechanisms leading 
to PKA inhibition by Rp cAMPS differ from those by H-89. The cyclic AMP 
analogue Rp cAMPS act at the cyclic AMP binding site (s) of the regulatory subunit 
of the enzyme (Rothermel et al., 1988), while H-89 inhibits protein kinase activity of 
the enzyme (Engh et al., 1996; Snyder et aL, 1992). 
Cicaprost produced 4.39 士 0.38，n = 3 fold increase in ERKl/2 activity with 
the basal normalised luciferase activity is 0.21 士 0.08，n = 3. Preincubating mlP-
CHO cells with H89 (10 and Rp cAMPS (10 for 30 min showed no 
significant influence in either basal or cicaprost-stimulated ERKl/2 activity (Fig. 
4.12). Results with the PKA inhibitors suggest that PKA is not involved in cicaprost-
stimulated ERKl/2 activity in mlP-CHO cells. 
4.2.4 Role of the Gq-mediated pathway in cicaprost-stimulated ERK1/2 
activation 
The best characterized effector of the PTX-insensitive Gq proteins is phospholipase 
C (PLC). When activated, PLC hydrolyses phosphatidylinositol yielding DAG and 
IP3. DAG is phosphorylated to form phosphatidic acid (PA), while inositol 1,4,5-
triphosphate is dephosphorylated and then recoupled with PA to form 
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phosphatidylinositol again. IP3 in turn releases calcium from intracellular stores 
while DAG activates membrane-bound protein kinase C (PKC). In the previous 
section, cicaprost was demonstrated to activate ERKl/2 in mlP-CHO cells in a PKA-
independent manner. As in Section 4.1，I demonstrated that a Gq-coupled purinergic 
receptor endogenously expressed in wild type CHO cells could stimulate ERKl/2 
activity. Therefore, I predicted that cicaprost-stimulated ERKl/2 activity occurs in a 
Gq-mediated fashion. 
4.2.4.1 Role of IP3 
IP3 releases calcium from intracellular stores leading to activation of a series of * 
phosphatases and kinases, which convert IP3 to a number of additional inositol 
phosphates. This process terminates the signaling activities of IP3 and salvages 
inositol for lipid re-synthesis. Lithium chloride, which has been shown to retard IP3 
degradation, was used to study the role of IP3 in cicaprost-stimulated ERKl/2 
activation in mlP-CHO cells. 
Cicaprost produced 4.39 土 0.38，n = 3 fold increase inERKl/2 activity with 
the basal normaiised luciferase activity is 0.21 土 0.08，n = 3. Preincubating the mlP-
CHO cells with lithium chloride (20 mM) to inhibit IP3 recycling for 30 min showed 
no significant effect on basal or cicaprost-stimulated ERKl/2 activity (Fig. 4.13). 
This suggested that IP3 does not take part in ERKl/2 activation in mlP-CHO cells. 
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4.2.4.2 Role of protein kinase C 
One of the most straightforward approaches to study the role played by PKC in 
ERKl/2 activation is to inhibit the enzymatic activity of this kinase. The non-specific 
PKC inhibitor, staurosporine, and specific PKC inhibitor, GF109203X, were 
therefore used. 
Cicaprost produced 4.39 土 0.38，n = 3 fold increase inERKl/2 activity with 
the basal normalised luciferase activity is 0.21 土 0.08，n = 3. Preincubating the mlP-
CHO cells with either staurosporine (1 |iM) or GF109203X (10 |iM) for 30 min 
showed no statistically significant effect on basal ERKl/2 activation alone (Fig. 4.14 
(A)). However, following incubation of 30 min both staurosporine and GF109203X 
significantly inhibited cicaprost-stimulated ERKl/2 activation to 0.61 土 0.53 and 
34.28 土 4.940/0 control cicapost response, n = 3, respectively (Fig. 4.15 (B)). 
Direct activation of PKC by 1 |iM PMA (30-min incubation) caused a 33.51 
士 9.62 fold increase in the basal ERKl/2 activity, n = 3. 
4.2.4.3 Conclusion < 
In conclusion, the PathDetect system and Western blot method showed that cicaprost 
could stimulate ERKl/2 in mlP-CHO cells in a concentration- and time-dependent 
manner. The ERKl/2 activation was completely inhibited by U0126 (10 jiM) 
indicating that activation of ERKl/2 is dependent on the phosphorylation of MEKl 
and MEK2. Results using the PathDetect system showed that high intracellular level 
of cyclic AMP has no effect on basal ERKl/2 activity, but greatly attenuates 
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cicaprost-stimulated ERKl/2 activation. However, neither PKA inhibitors showed 
any effect on basal or cicaprost-stimulated ERKl/2 activation indicating that 
stimulation of ERKl/2 activation is independent of PKA. IP3 did not take part in 
cicaprost-stimulated ERKl/2 activation, two PKC inhibitors greatly inhibit this 
activation by blocking the action of PKC. In western blot, PKC activator (PMA) 
further proved that PKC can activate ERKl/2 activation, also in a MEK-dependent 
manner. 
4.2.5 IP-receptor activation of ERK1/2 in hIP-CHO cells 
The human IP-receptor was first isolated and cloned in 1994 (Boie et al., 1994; 
Katsuyama et al., 1994). When comparing the amino acid sequences ofhIP and mlP-
receptors, Katsuyama showed the hIP-receptor is 73% identical to that of the mlP-
receptor (Katsuyama et al,, 1994). On signal transduction analysis of the mlP-
receptor, I found that mlP-receptor could activate ERKl/2 activity in CHO cells in a 
Gq-mediated pathway. Next, I want to examine this signaling pathway for the hlP-
receptor. Preliminary studies with hlP-receptor were performed using Western blot 
methods because of the high cost of the PathDetect system. 
4.2.5.1 Activation of ERK1/2 in hlP-CHO cells 
To study the regulation of ERKl/2 by hlP-receptors, hIP-CHO cells were used and 
assayed using western blot as describe in Chapter 3. In Figure 4.15, cicaprost (10 |iM) 
produced a time-dependent activation of ERKl/2 in hIP-CHO cells with no change 
in total ERKl/2 in each sample, giving a peak activation of ERKl/2 occurring at 2 to 
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10 min. Incubation ofhIP-CHO cells with PMA (1 ^M) for 10 min showed a marked 
enhancement in ERKl/2 activation indicating that PKC stimulates ERKl/2 in hlP-
CHO cells. Figure 4.16 shows that incubating hIP-CHO cells with cicaprost (10 \ M ) 
for 10 min gives about a 2.6-fold increase compared to the basal ERKl/2 activation 
when expressed in density (IDV), as described in Chapter 3. Both the basal and 
cicaprost-stimulated ERKl/2 activation could be completely inhibited by 
preincubating the cells with U0126 (10 ^iM) for 30 min (Fig. 4.16). Results therefore 
show that activation of ERKl/2 in hIP-CHO cells occurs in a MEK-dependent 
manner. 
I 
4.2.5.2 Role of the Gq-mediated pathway in cicaprost-stimulated 
ERK1/2 activation 
As I demonstrated that mlP-CHO cells could activate ERKl/2 in a PKC-dependent 
fashion, a PKC inhibitor (staurosporine) was also tested here in hIP-CHO cells. 
Figure 4.17，Western blot showed cicaprost (10 \iM) produced a 2.6-fold increase in 
basal ERKl/2 activation following 10 min incubation. Preincubation with < 
staurosporine (1 |aM) for 30 min seems to have no effect on both basal and cicaprost-
stimulated ERKl/2 activation. As it is a preliminary experiment in hIP-CHO cells, 
further investigations need to be conducted to confirm the effect of PKC inhibition 
on cicaprost-stimulated ERKl/2 activation in hIP-CHO cells. 
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4.2.5.3 Role of the Gs-mediated pathway in cicaprost-stimulated 
ERK1/2 activation 
Previous experiments with the PathDetect system in mlP-CHO cells showed that 
forskolin (10 [iM) inhibited cicaprost-stimulated ERKl/2 activation by mimicking 
the effect of adenylyl cyclase to maintain a high level of intracellular cyclic AMP. 
Therefore, I suspected that an inhibitory effect of Gs-mediated pathway would also 
be seen in hIP-CHO cells. 
In Figure 4.18，10 min cicaprost (10 \iM) stimulated ERKl/2 activation by 
1.77-fold basal. Preincubation with forskolin (10 |iM) for 30 min showed no effect 
on either basal or cicaprost-stimulated ERKl/2 activation suggesting that cyclic 
AMP may not take part in the regulation of ERKl/2 activity in hIP-CHO cells. 
However, preincubation of Rp cAMPS (10 |iM)，a PKA inhibitor, for 30 min did 
seem to attenuate the cicaprost-stimulated ERKl/2 activation in hIP-CHO cells, 
indicating that PKA may take an inhibitory action to cicaprost-stimulated ERKl/2 
activation. In order to confirm the influence of adenylyl cyclase on cicaprost-
stimulated ERK'1/2, effective adenylyl cyclase inhibitors should be employed which 
would be predicted to enhance cicaprost-stimulated ERKl/2 activity. SQ22536 and 
MDL12330A are commonly used adenylyl cyclase inhibitor (Guellaen et al., 1977; 
Harris et al., 1979). However, both adenylyl cyclase inhibitors failed to effectively 
inhibiting cicaprost-stimulated [^H]-cyclic AMP accumulation and both interfered 
with the [^H]-inositol phosphate assay (Kevin Chow and Jason Kam; unpublished 
observations). 
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Another means to study the influence of IP-receptor-stimulated cyclic AMP 
on ERKl/2 activation is to use a constitutively active mutant of God (GizQL) to 
inhibit the activity of adenylyl cyclase. As the concentration of cDNA which can be 
transfected into cells is limited by toxicity, it was necessary to find an optimised 
cDNA concentration of hIP-receptor and the effective concentration of GizQL to 
inhibit adenylyl cyclase activity. To find an optimised cDNA concentration of hlP-
receptor, increasing amount of hIP-receptor cDNA was transfected into CHO cells 
and the total amount of DNA was balanced with vector DNA (pcDNAl.l). 
pcDNAl.l was used because this is the expression vector for GizQL. To find the 
effective concentration of GnQU the cells were transfected with increasing amount 
of Gi2QL in addition to hlP-receptor or vector DNA. 
The effect of pcDNAl.l was studied in western blot (Fig. 4.19). Cicaprost 
(10 \iM) stimulated ERKl/2 activation to 2.02-fold increase compared to the basal 
response in CHO cells transfected with hlP-receptor cDNA (1.0 ^ig/ml) only. In 
CHO cells transfected with different concentrations of hIP-receptor and vector 
cDNA (pcDNAl.l), basal and cicaprost (100 nM and 10 |aM) responses showed a < 
consistently high level of stimulated ERKl/2 activation. 
In Figure 4.20 (A), there is no effect of the transfection reagents or 
pcDNAl.l on [^H]-cyclic AMP accumulation in CHO cells. CHO cells transfected 
with hIP-receptor cDNA showed a concentration-dependent increase in cicaprost-
stimulated [^H]-cyclic AMP accumulation (Fig. 4.19 (B). The more hlP-receptor 
transfected into cells, the higher the cicaprost-stimulated response. 
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When transfecting the hIP-CHO cells with different concentrations of GizQL, 
high concentrations of GizQL (1.05 and 1.18 |ag/ml) inhibited the [^H]-cyclic AMP 
accumulation (Fig 4.21). However, the hIP-CHO cells with vector cDNA showed a 
high level of [^H]-cyclic AMP accumulation (Fig 4.21(B)). It is possible that vector 
cDNA can enhance the expression of hlP-receptor cDNA into the cells. The ERKl/2 
activation in hIP-CHO cells is still under investigation. 
4.2.5.4 Conclusions 
In the hIP-CHO cells, activation of ERKl/2 was demonstrated in a time-dependent 
manner giving peak activation at 2-10 min. Using 10-min incubation of cicaprost (10 
^M) in hIP-CHO cells, activation of ERKl/2 was completely inhibited by 30 min 
incubation with U0126 (10 |iM), indicating that ERKl/2 activation is mediated by 
MEK. 
Staurosporine (1 \iM) showed no effect on cicaprost-stimulated ERKl/2 
activation in hIP-CHO cells. This observation was different from that obtained in 
mlP-CHO cells using the PathDetect system. To confirm the effect of PKC on 
ERKl/2 activation in hIP-CHO cells, more experiments and more specific PKC 
inhibitors should be used. 
To study the effect of Gs-mediated pathway on cicaprost-stimulated ERKl/2 
activation, an adenylyl cyclase activator (forskolin) and PKA inhibitor (Rp cAMPS) 
were used. Surprisingly, forskolin showed no effect on basal or cicaprost-stimulated 
ERKl/2 activation in hIP-CHO cells indicating that cyclic AMP does not take part in 
regulation of ERKl/2 activation in these cells. However, incubating hIP-CHO cells 
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with Rp cAMPS (10 ^iM) for 10 min, cicaprost-stimulated ERKl/2 activation was 
attenuated. 
Employing a constitutively-active mutant of God (Gj2QL), preliminary results 
showed that Gi2QL can inhibit [^H]-cyclic AMP accumulation in response to 
cicaprost at high concentration. Therefore, Gi2QL can be used as a tool to inhibit 
adenylyl cyclase activity. However, interesting results showed that CHO cells 
transfected with vector cDNA (pcDNAl.l) potentiated [^H]-cyclic AMP 
accumulation and ERKl/2 activation in hIP-CHO cells probably due to facilitation of 
expression of hlP-receptor in the cells by pcDNAl.l. 
/ 
4.2.6 IP-receptor activation of ERK1/2 in neuroblastoma cells 
4.2.6.1 Rat/mouse neuroblastoma/glioma (NG108-15) cells 
Cicaprost produced a concentration-dependent increase in [^H]-cyclic AMP and 
[^H]-inositol phosphate accumulation in NG108-15 cells, which endogenously 
express rat/mouse IP-receptors (Fig. 4.7). Therefore, cicaprost-stimulated ERKl/2 
i 
activation may be similar to that of mlP-CHO cells. However, cicaprost (10 |iM) 
failed to stimulate ERKl/2 in NG108-15 cells (Fig. 4.22). Using PMA (1 |iM) as a 
positive control, preincubating cells with PMA for 10 min also failed to show any 
activation in 2 experiments. However, a high level of ERKl/2 activation with PMA 
for 10 min was observed in one experiment. When stimulating the cells with 
bradykinin (1 |LIM), which stimulates Gq-coupled bradykinin receptors in NG108-15 
cells (Jason Kam, unpublished observations), activation of ERKl/2 showed a time-
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dependent increase with peak at 15 min (Fig. 4.23). Surprisingly, in addition to 
detecting pERKl/2 at 44/42 kDa, a strong band (around 130 kDa) was observed in 
all the NG108-15 cells. This additional band may be due to the incomplete lysis of 
the cells resulting in a high molecular weight protein located at the top of the gel. 
However, a longer incubation time of the cells in lysis buffer failed to diminish this 
phenomenon showing that this high molecular weight protein may not be the result 
of insufficent lysis. 
Although the EP-receptor in NG108-15 cells can couple to Gq, the failure of 
PMA to activate ERKl/2 precludes this as a pathway coupling IP-and bradykinin-
receptors to ERKl/2. The ERKl/2 cascade in NG108-15 cells is still under 
investigation. 
4.2.6.2 Human neuroblastoma (SK-N-SH) cells 
As shown in Figure 4.7, cicaprost can only produce [^H]-cyclic AMP accumulation 
in a concentration dependent manner in SK-N-SH cells. In most cells, cyclic AMP 
serves to inhibit ERKl/2 activation by inhibiting Raf-1 activation. However, due to 
< 
the preferential activation of different Raf isoforms in a cell-specific manner, cyclic 
AMP in PC12 cells is more likely to activate ERKl/2 due to the presence of B-Raf 
(Cavanaugh et aL, 2001). Therefore, only the presence of B-Raf in SK-N-SH cells 
would be expected to produce a cicaprost-stimulated ERKl/2 activation response. 
In Western blotting study using SK-N-SH cells, cicaprost (10 ^iM) failed to 
stimulate ERKl/2 (Fig. 4.22). However, the PKC activator, PMA caused activation 
of ERKl/2 (Fig. 4.22). As bradykinin can stimulate PLC by coupling to Gq, I used 
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bradykinin to test whether Gq-coupled receptor activate ERKl/2 activation in SK-N-
SH cells. Bradykinin (1 }iM) failed to show a time-dependent increase in ERKl/2 
activity in SK-N-SH cells (Fig. 4.25). In addition, there is no study to investigate the 
existence of B-Raf in these cells. Therefore, the lack of stimulation of ERKl/2 
activity in SK-N-SH cells with bradykinin and cicaprost is probably due to the failure 
of IP-receptors to couple to Gq in these cells (Kam et al, 2001). 
< 
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Figure 4.6 Activation of adenylyl cyclase, phospholipase C and ERKl/2 in mlP-
CHO cells. [^H]-cyclic AMP accumulation, [^H]-inositol phosphate accumulation 
and ERKl/2 activation were determined as described in Chapter 3. Values are 
means 土 S.E.M. for at least 3 experiments. [^H]-cyclic AMP accumulation has 
been normalised against the maximum fitted response to cicaprost in each 
experiment (10.03 土 1.29 fold basal), with the basal activity of 0.11 土 0.03% < 
conversion. [^H]-inositol phosphate accumulation has been normalised against the 
maximum fitted response to cicaprost in each experiment (4.79 土 1.03 fold basal), 
with the basal activity of 5.00 土 0.87o/o conversion. ERKl/2 activity has been 
normalised against the maximum fitted response to cicaprost in each experiment 
(4.95 土 0.07 fold basal), with the basal activity of 0.12 士 0.06 normalised firefly 
luciferase activity. 
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Figure 4.7 IP-receptor activation of adenylyl cyclase (AC) and phospholipase C 
(PLC) in NG108-15 (A) and SK-N-SH (B) cells. [^H]-cyclic AMP and [^H]-inositol 
phosphate accumulation was determined as described in Chapter 3. Values are means 
土 S.E.M. for at least 3 experiments. [^H]-cyclic AMP accumulation has been 
normalised against the maximum fitted response to cicaprost in each experiment. 
NG108-15 cells have maximum 58.8 士 14.43 fold basal and SK-N-SH cells have 
34.29 土 18.63 fold basal response with the basal activity of 0.18 土 0.06 and 0.07 土 
0.03% conversion, respectively. [^H]-inositol phosphate accumulation has been 
normalised against the maximum fitted response to cicaprost in each experiment. 
NG108-15 cells have maximum 6.53 士 0.17 fold basal response with basal activity of 
6.66 士 1.350/0 conversion 
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Figure 4.8 Western blot showing time course of cicaprost-stimulated ERKl/2 in 
mlP-CHO cells. A 10 min incubation with PMA was used as a positive control. CHO 
cells were transfected with mlP-receptor cDNA (0.5 |ig/ml) and assayed following 
serum starvation overnight (see Chapter 3). Results are representative of three < 
independent experiments. 
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Figure 4.9 Effect of U0126 on cicaprost-stimulated ERKl/2 activation in mlP-CHO 
cells. (A) Representative autoradiograph showing pERKl/2 (B) pERKl/2 was 
quantitated by FluorChem Imager. CHO cells were transfected with mlP-receptor 
cDNA (0.5 |ig/ml), and assayed following serum starvation overnight (see Chapter 3). 
Cell samples were lysed following 10 min incubation with cicaprost or medium. 
Results are representative of two independent experiments. 
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Figure 4.10 Effect of U0126 on PMA-stimulated ERKl/2 activation in mlP-CHO < 
cells. (A) Representative autoradiograph showing pERKl/2. (B) pERKl/2 was 
quantitated by FluorChem Imager. CHO cells were transfected with mlP-receptor 
cDNA (0.5 i^ g/ml)，and assay following serum starvation overnight (see Chaopter 3). 
Cell samples were lysed following 10 min incubation with cicaprost, PMA or 
medium. Results are representative of two independent experiments. 
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Figure 4.11 Effect of forskolin and IBMX alone (A) or on 100 nM cicaprost-< 
stimulated (B) ERKl/2 activation in mlP-CHO cells. Cells were preincubated with 
forskolin or IBMX for 30 mins and tested with HBS or cicaprost for a further 5 h 
(see Chapter 3). The basal and cicaprost-stimulated ERKl/2 activity is 0.17 士 0.07 
and 0.59 士 0.27 normalised luciferase activity, n = 4, respectively. Each compund 
was assessed three times over four experiments. Results in figure represent mean 土 
S.E.M., n 二 3，of experiments performed in duplicate. (* p<0.05; ** p<0.01) 
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Figure 4.12 Effect of H89 and Rp cAMPS alone (A) or on 100 nM cicaprost-
stimulated (B) ERKl/2 activation in mlP-CHO cells. Cells were preincubated with 
H-89 or Rp cAMPS for 30 mins and tested with HBS or cicaprost for a further 5 h 
(see Chapter 3). The control basal and cicaprost-stimulated ERKl/2 activity is 0.21 土 
0.08 and 0.75 土 0.31 normalised luciferase activity, n = 3，respectively. Result 
represents mean 士 S.E.M. of three experiments, performed in duplicate. 
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Figure 4.13 (A) Effect of lithium chloride alone (A) or on 100 nM cicaprost-
stimulated (B) ERKl/2 activation in mlP-CHO cells. Cells were preincubated with 
lithium chloride for 30 mins and tested with HBS or cicaprost for a further 5 h (see 
Chapter 3). The control basal and cicaprost-stimulated ERKl/2 activity is 0.21 士 0.08 
and 0.75 土 0.31 normalised luciferase activity, n 二 3，respectively. Result represents 
mean 土 S.E.M. of three experiments, performed in duplicate. 
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(A) Basal ERK1/2 activity 
^ 150-1 
"oT ~ 
B它100 M 鐘 … 
II n _ _ 
s i 50- ^ M 
oJ _ ^ _ 
control stau GF 
(1 jiM) (10 ^M) 
(B) Cicaprost-stimulated ERK1/2 activity 
1 0 0 - 1 — - 1 
-oT 
Q w 50. ** 
•！ ** _ 
q J  
control stau GF 
( 1 | I M ) ( 1 0 | IM) 
Figure 4.14 Effect of staurosporine (stau) and GF109203X (GF) alone (A) or on 100 
nM cicaprost-stimulated (B) ERKl/2 activation in mlP-CHO cells. Cell were 
preincubated with staurosporine or GF109203X for 30 mins and tested with HBS or 
cicaprost for a further 5 h (see Chapter 3). The control basal and cicaprost-stimulated 
ERKl/2 activity is 0.21 土 0.08 and 0.75 土 0.31 normalised luciferase activity, n = 3， 
respectively. Result represents mean 士 S.E.M. of three experiments, performed in 
duplicate. (** p<0.01) 
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Figure 4.15 Western blot showing time course of cicaprost-stimulated ERKl/2 
activity in hIP-CHO cells. A 10 min incubation with PMA was used as a positive 
control. CHO cells were transfected with hlP-receptor cDNA (1.0 ^g/ml) and 
assayed following serum starvation overnight (see Chapter 3). Results are 
representative of three independent experiments 
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Figure 4.16 Effect of U0126 on basal and cicaprost-stimulated ERKl/2 activation in 
hIP-CHO cells. (A) Representative autoradiograph showing pERKl/2 (upper panel) 
and ERKl/2 (lower panel). (B) pERKl/2 was quantitated by FluorChem Imager. 
CHO cells were transfected with hIP-receptor cDNA (1.0 jig/ml) and assayed 
following serum starvation overnight (see Chapter 3). Cell samples were lysed 
following 10 min incubation with cicaprost or medium. Results are representative of 
two independent experiments. 
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Figure 4.17 Effect of staurosporine (stau) on basal and cicaprost-stimulated ERKl/2 
activation in hIP-CHO cells. (A) Representative autoradiograph showing pERKl/2 
(upper panel) and ERKl/2 (lower panel). (B) pERKl/2 was quantitated by 
FluorChem Imager. CHO cells were transfected with hIP-receptor cDNA (1.0 }ig/ml) 
and assayed following serum starvation overnight (see Chapter 3). Cell samples were 
lysed following 10 min incubation with cicaprost or medium. Results come from one 
experiment. 
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Figure 4.18 Effect of Rp cAMPS (Rp) and forskolin (for) on basal and cicaprost i 
(cica)-stimulated ERKl/2 activation in hIP-CHO cells. (A) Representative 
autoradiograph showing pERKl/2 (upper panel) and ERKl/2 (lower panel). (B) 
pERKl/2 was quantitated by FluorChem Imager. CHO cells were transfected with 
hlP-receptor cDNA (1.0 ^ig/ml) and assayed following serum starvation overnight 
(see Chapter 3). Cell samples were lysed 'following 10 min incubation with cicaprost 
or medium. Results come from one experiment. 
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Figure 4.19 Western blot showing the effect of different concentrations of hIP cDNA 
transfected on cicaprost (Cica)-stimulated ERKl/2 activation in CHO cells. CHO 
cells were transfected and assayed following serum starvation overnight (see Chapter 
3). Cell samples were lysed following 10 min incubation with cicaprost or medium. 
Results come from one experiment. 
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Figure 4.20 Effect of different concentrations of hIP on cicaprost-stimulated [^H]-
cyclic AMP accumulation in transfected CHO cells. CHO cells were transfected and 
assayed (see Chapter 3). Results come from one experiment, performed in duplicate. 
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Figure 4.21 Effect of cicaprost in the presence of consitutively active mutant of Gi 
(GizQL) (A) or vector DNA (pcDNA 1.1) (B) on [^H]-cyclic AMP accumulation in 
CHO cells with different concentrations of hIP. CHO cells were transfected as 
described in Chapter 3. Results come from one experiment, performed in duplicate. “ “ “ ‘ Page 132 
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Figure 4.22 Western blot showing time course of cicaprost-stimulated ERKl/2 in 
NG108-15 cells. A 10 min incubation with PMA was used as a positive control. 
NG108-15 cells were assayed following serum starvation overnight (see Chapter 3). 
Results are representative of two independent experiments. 
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Figure 4.23 Western blot showing time course of bradykinin stimulated ERKl/2 in 
NG108-15 cells. A 10 min incubation with PMA was used as a positive control. 
NG108-15 cells were assayed following serum starvation overnight as described in 
Chpater 3. Results are from one experiment 
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Figure 4.24 Western blot showing time course of cicaprost-stimulated ERKl/2 in 
SK-N-SH cells. A 10 min incubation with PMA was used as a positive control. SK-
N-SH cells Were assayed following serum starvation overnight (see Chapter 3). 
Results are representative of three independent experiments. 
‘ "“ ‘ Page 135 
Chapter 4 Results 
bradykinin PMA 
(1 _ ) ( l i iM) 
time (min) 0 2 5 10 15 30 10 
pERK1 丨2 诱 廉 愈 广 “ ~ ^ 一 . � , .1 丨 I， 
Figure 4.25 Western blot showing time course of bradykinin-stimulated ERKl/2 in 
SK-N-SH cells. A 10 min incubation with PMA was used as a positive control. SK-
N-SH cells were assayed following serum starvation overnight (see Chapter 3). 
Results are from one experiment. 
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Chapter 5 
General Discussion and Conclusions 
The aim of this project was to examine the ability of IP-receptors to regulate 
the ERKl/2 cascade and to define any crosstalk between Gs- and Gq-mediated 
pathways in transient transfection systems in CHO cells and in neuronal cell lines 
endogenously expressing IP-receptors. In this study, two newly developed methods 
were used to detect the ERKl/2 activation in the cells. The PathDetect system was » 
used to detect ERKl/2 activity in cells, which were transfected with mlP-receptor. In 
order to reduce the cost of the experiments, Western blot methods were then used in 
the study of hIP-receptors and for cells with poor transfection efficiency such as 
NG108-15 cells and SK-N-SH cells. 
With the low luciferase activity in mammalian cells, firefly luciferase reporter 
gene in the PathDetect system is a useful tool to quantify the ERKl/2 activation in 
CHO cells. First, with the use of positive control plasmid and negative control 
plasmid, we can see that the firefly luciferase activity is reflecting the ERKl/2 
activation in CHO cells in a MEK-dependent manner. However, without transfection 
of an activation domain of Elk-1, we cannot see any change in firefly luciferase 
activity, showing that upstream kinase could not activate transcription of firefly 
luciferase gene expression by their own. 
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Without the transfection of IP-receptor cDNA, there is no cicaprost-
stimulated ERKl/2 activity indicating that cicaprost-stimulated ERKl/2 found in 
mlP-CHO cells are due to the transfected mlP-receptor. With the use of the two 
MEK inhibitors (U0126 and PD098059), luciferase activity was shown to reflect the 
Elk-1 activation through the ERKl/2 cascade, but not the JNK cascade. Finally, the 
PathDetect system condition were then be optimised with the total cDNA inside the 
cells to reduce the toxicity of the transfection reagents and account for any difference 
in transfection efficiency and cell number. 
In the mlP-CHO cells, cicaprost-stimulated ERKl/2 activity was shown in a 
concentration- and time-dependent manner. The cicaprost-stimulated ERKl/2 t 
activation was significantly inhibited by two MEK inhibitors (U0126 and PD098059) 
indicating that mlP-receptors stimulate the Elk-1 activity by phosphorylation of 
ERKl/2 rather than JNK kinase. 
With the use of forskolin and IBMX, cyclic AMP inhibited the cicaprost-
stimulated ERKl/2 activation without affecting the basal ERKl/2 activity. However, 
two PKA inhibitors (H89 and Rp cAMPS) failed to show any effect on cicaprost-
stimulated ERKl/2 activation. It is possible that the inhibitory effect of cyclic AMP 
on ERKl/2 activity was independent of PKA activity, or that the PKA inhibitors 
were insufficiently effective. 
Lithium chloride also showed no effect on the cicaprost-stimulated ERKl/2 
activity indicating that IP3 does not take part in activation of the ERKl/2 cascade in 
mlP-CHO cells. With the use of two PKC inhibitors (staurosporine and GF109203X)， 
cicaprost-stimulated ERKl/2 activation was inhibited indicating that PKC take a 
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stimulatory role in EKRl/2 cascade. The role of PKC was further verified by the use 
of PKC activator (PMA). Stimulation of PKC showed a huge increase in the ERKl/2 
indicating that PKC can activate ERKl/2 in mlP-CHO cells. Taken together, mlP-
receptor expressed in CHO cells appear to stimulate ERKl/2 cascade though 
coupling to Gq proteins, but this response is likely to be attenuated by coupling to Gs. 
In the western blot study, the activated ERKl/2 and the total endogenous 
ERKl/2 were directly detected with specific antibodies against pERKl/2 and 
ERKl/2. A positive control (PMA) was used to show the low level of IP-receptor 
stimulate ERKl/2 activation is not due to the poor sensitivity of this assay. With the 
inconsistency of the band density between different experiments due to unstable 
property of the reagents used in western blot, the densitometer reading of the 
activated ERKl/2 can only be used as a reference in the same experiment. 
Cicaprost stimulated ERKl/2 activity in hIP-CHO cells in a time-dependent 
manner with the peak activation at 2 to 10 min. This activation was then completely 
inhibited by the U0126 indicating that cicaprost-stimulated ERKl/2 activation occurs 
in a MEK-dependent manner. U0126 also inhibited the PMA-stimulated ERKl/2 
i activation. 
PKC inhibition (staurosporine) failed to show effect on ERKl/2 activation. 
This experiment needs to be repeated to confirm the effect of PKC on ERKl/2 
activation. However, forskolin showed no effect on the cicaprost-stimulated ERKl/2 
activity while PKA inhibitor (Rp cAMPS) showed a slight decrease in cicparost-
stimulated ERKl/2 in hIP-CHO cells. These results are contradictory to what we 
have obtained in mlP-CHO cells using the PathDetect assay. These contradictory 
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results in mlP-CHO and hIP-CHO cells maybe due to the low sensitivity of western 
blot study and need to be confirmed by further study. 
Preliminary results using active mutant of Gai (Gi2QL) suggested that high 
concentration of GizQL inhibited the [^H]-cyclic AMP accumulation in hIP-CHO 
cells. As I need to optimise the toxicity of the transfection reagents to the cell with 
the efficiency of Gi2QL inhibiting cyclic AMP production, further investigation have 
to be performed. 
Rat/mouse neuroblastoma/glioma (NG108-15) and human neuroblastoma 
(SK-N-SH) cells, which endogenously express IP-receptors, were also studied. 
Cicaprost produced a concentration-dependent increase in the [^H]-cyclic AMP and 
[^H]-inositol phosphate accumulation in NG108-15 cells. I predicted that rat/mouse 
IP-receptor endogenously expressed in NG108-15 cells should show similar ability 
of ERKl/2 activation compared to mlP-CHO cells. However, cicaprost and PMA 
failed to show activate ERKl/2. A Gq-coupled bradykinin receptor, which is 
endogenously expressed in NG108-15 cells, stimulated ERKl/2 in a time-dependent 
manner giving peak activation at 15 min. Stimulation of bradykinin receptor can also 
activate ERKl/2 cascade through tyrosine kinase phosphorylation in the rat 
mesangial cells (El-Dahr et al., 1998). In order to verify the bradykinin-stimulated 
ERKl/2 activation, tyrosine kinase and PI3K inhibitors can be used to dissect the 
activation ERKl/2 pathway by bradykinin in these cells. 
Because the IP-receptor in NG108-15 cell can couple to Gq and the Gq-
coupled bradykinin receptor can stimulate ERKl/2 activation in NG108-15 cells, the 
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failure of cicaprost- or PMA-stimulated ERKl/2 activation is unexpected and is still 
being investigated. 
In SK-N-SH cells, which endogenously expressing human IP-receptors, 
cicaprost failed to stimulate [^H]-inositol phosphate accumulation (Kam et al., 2001). 
However, cyclic AMP can activate ERKl/2 due to the preferential coupling to Raf 
isofom such as B-Raf in PC12 cells (Cavanaugh et aL, 2001). I predicted that IP-
receptors expressed in SK-N-SH cells can only activation ERKl/2 in the presence of 
B-Raf. However, results showed that cicaprost and bradykinin failed to stimulated 
ERKl/2 activation. This may due to the failure of IP-receptor coupling to Gq in these 
cells or the absence of B-Raf. To verify the failure of ERKl/2 activation due to the 
inefficient coupling to B-Raf, we can detect the level of B-Raf isoform in SK-N-SH 
cells using specific antibody against B-Raf or tranfecting a constitutively active 
mutant of B-Raf to show any ERKl/2 activation in these cells. In addition a low 
sensitivity of Western blotting could also account for the weak signal to produce 
sufficient response in these cells. 
« 
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